

## Inhaltsverzeichnis

<b>Charakterisierung der Studienpopulationen.....</b>	<b>2</b>
<b>Morbidität .....</b>	<b>34</b>
Blutungen .....	34
Alle Blutungsepisoden.....	34
Behandelte Blutungsepisoden.....	35
Behandelte Spontanblutungsepisoden .....	36
Behandelte traumatische Blutungsepisoden .....	37
Behandelte Blutungsepisoden aufgrund einer Operation oder eines anderen Eingriffs .....	38
Gelenkblutungsepisoden.....	39
Zielgelenkblutungsepisoden .....	40
Gelenkgesundheit.....	41
HJHS - Total Score.....	41
HJHS - Structural Score .....	45
HJHS - Functional Score .....	49
EQ-5D VAS .....	53
Körperliche Aktivität .....	57
<b>Lebensqualität .....</b>	<b>105</b>
CATCH .....	105
< 8 Jahre/Caregiver.....	105
8 - 17 Jahre .....	113
≥ 18 Jahre.....	149
EMI-Pref .....	189
≥ 12 Jahre.....	189
Präferenz .....	189
Faktoren.....	190
Caregiver (unter 18 Jahre) .....	204
Präferenz .....	204
Faktoren.....	205
<b>Verträglichkeit.....</b>	<b>219</b>
Inklusive disease-related events.....	219
Hauptkategorien.....	219
SOC/PT .....	227
AESI .....	263
Outcome.....	282
Exklusive disease-related events.....	283

POPULATION: All Treated Patients

ENDPOINT: --

MODEL: --

STUDY: BO41423

Demographics and Baseline Characteristics

Name	Level		Emicizumab (N=72)
Sex			
All	n/a	n	72
		Male	69 (95.8%)
		Female	3 ( 4.2%)
Hemophilia severity	Mild	n	21
		Male	19 (90.5%)
		Female	2 ( 9.5%)
	Moderate	n	51
		Male	50 (98.0%)
		Female	1 ( 2.0%)
Age			
All	n/a	n	72
		Mean (SD)	26.0 (17.1)
		Q1 - Q3	12.0 - 36.5
		Median	23.5
		Min - Max	2 - 71
Hemophilia severity	Mild	n	21
		Mean (SD)	33.5 (19.0)
		Q1 - Q3	21.0 - 49.0
		Median	29
		Min - Max	6 - 71
	Moderate	n	51
		Mean (SD)	22.9 (15.5)
		Q1 - Q3	10.0 - 35.0

		Median	19
		Min - Max	2 - 56
Age category 1			
All	n/a	n	72
		< 18	30 (41.7%)
		>= 18	42 (58.3%)
Hemophilia severity	Mild	n	21
		< 18	5 (23.8%)
		>= 18	16 (76.2%)
	Moderate	n	51
		< 18	25 (49.0%)
		>= 18	26 (51.0%)
Age category 2			
All	n/a	n	72
		< 65	70 (97.2%)
		>= 65	2 ( 2.8%)
Hemophilia severity	Mild	n	21
		< 65	19 (90.5%)
		>= 65	2 ( 9.5%)
	Moderate	n	51
		< 65	51 ( 100%)
		>= 65	0
Age category 3			
All	n/a	n	72
		2 - < 6	5 ( 6.9%)
		6 - <12	11 (15.3%)
		12 - <18	14 (19.4%)
		18 - <65	40 (55.6%)
		>= 65	2 ( 2.8%)
Hemophilia severity	Mild	n	21
		2 - < 6	0
		6 - <12	2 ( 9.5%)
		12 - <18	3 (14.3%)
		18 - <65	14 (66.7%)

		>= 65	2 ( 9.5%)
	Moderate	n	51
		2 - < 6	5 ( 9.8%)
		6 - <12	9 (17.6%)
		12 - <18	11 (21.6%)
		18 - <65	26 (51.0%)
		>= 65	0
Race			
All	n/a	n	72
		Asian	3 ( 4.2%)
		Black or African American	6 ( 8.3%)
		White	61 (84.7%)
		Unknown	2 ( 2.8%)
Hemophilia severity	Mild	n	21
		Asian	1 ( 4.8%)
		Black or African American	1 ( 4.8%)
		White	18 (85.7%)
		Unknown	1 ( 4.8%)
	Moderate	n	51
		Asian	2 ( 3.9%)
		Black or African American	5 ( 9.8%)
		White	43 (84.3%)
		Unknown	1 ( 2.0%)
Ethnicity			
All	n/a	n	72
		Hispanic or Latino	1 ( 1.4%)
		Not Hispanic or Latino	61 (84.7%)
		Not Reported	7 ( 9.7%)
		Unknown	3 ( 4.2%)
Hemophilia severity	Mild	n	21
		Hispanic or Latino	0
		Not Hispanic or Latino	18 (85.7%)
		Not Reported	2 ( 9.5%)
		Unknown	1 ( 4.8%)
	Moderate	n	51

		Hispanic or Latino	1 ( 2.0%)
		Not Hispanic or Latino	43 (84.3%)
		Not Reported	5 ( 9.8%)
		Unknown	2 ( 3.9%)
Dosing regimen at enrollment			
All	n/a	n	72
		1.5 mg/kg QW	25 (34.7%)
		3 mg/kg Q2W	39 (54.2%)
		6 mg/kg Q4W	8 (11.1%)
Hemophilia severity	Mild	n	21
		1.5 mg/kg QW	9 (42.9%)
		3 mg/kg Q2W	9 (42.9%)
		6 mg/kg Q4W	3 (14.3%)
	Moderate	n	51
		1.5 mg/kg QW	16 (31.4%)
		3 mg/kg Q2W	30 (58.8%)
		6 mg/kg Q4W	5 ( 9.8%)
Height (cm)			
All	n/a	n	70
		Mean (SD)	163.32 (25.25)
		Q1 - Q3	155.00 - 180.00
		Median	171.75
		Min - Max	96.0 - 198.0
Hemophilia severity	Mild	n	21
		Mean (SD)	170.93 (15.95)
		Q1 - Q3	170.00 - 181.00
		Median	176
		Min - Max	118.5 - 185.0
	Moderate	n	49
		Mean (SD)	160.07 (27.83)
		Q1 - Q3	143.00 - 180.00
		Median	170
		Min - Max	96.0 - 198.0
Weight (kg)			

All	n/a	n	72
		Mean (SD)	70.90 (32.81)
		Q1 - Q3	41.50 - 88.95
		Median	75.65
		Min - Max	13.5 - 141.0
Hemophilia severity	Mild	n	21
		Mean (SD)	81.94 (31.17)
		Q1 - Q3	66.50 - 86.50
		Median	79.9
		Min - Max	20.1 - 141.0
	Moderate	n	51
		Mean (SD)	66.35 (32.67)
		Q1 - Q3	35.20 - 89.00
		Median	72
		Min - Max	13.5 - 134.2
BSA (m2)			
All	n/a	n	70
		Mean (SD)	1.73 (0.52)
		Q1 - Q3	1.36 - 2.06
		Median	1.93
		Min - Max	0.6 - 2.6
Hemophilia severity	Mild	n	21
		Mean (SD)	1.92 (0.42)
		Q1 - Q3	1.76 - 2.07
		Median	1.95
		Min - Max	0.8 - 2.5
	Moderate	n	49
		Mean (SD)	1.65 (0.55)
		Q1 - Q3	1.19 - 2.06
		Median	1.82
		Min - Max	0.6 - 2.6
BMI (kg/m2)			
All	n/a	n	70
		Mean (SD)	24.22 (6.91)
		Q1 - Q3	17.43 - 27.76

		Median	24.61
		Min - Max	14.1 - 45.0
Hemophilia severity	Mild	n	21
		Mean (SD)	27.12 (8.06)
		Q1 - Q3	21.14 - 31.02
		Median	26.03
		Min - Max	14.3 - 45.0
	Moderate	n	49
		Mean (SD)	22.97 (6.02)
		Q1 - Q3	17.16 - 27.10
		Median	23.04
		Min - Max	14.1 - 36.8
Did the patient have an inhibitor			
All	n/a	n	72
		Yes	2 ( 2.8%)
		No	70 (97.2%)
Hemophilia severity	Mild	n	21
		Yes	1 ( 4.8%)
		No	20 (95.2%)
	Moderate	n	51
		Yes	1 ( 2.0%)
		No	50 (98.0%)
Highest historical inhibitor titer			
All	n/a	n	2
		Mean (SD)	1.10 (0.14)
		Q1 - Q3	1.00 - 1.20
		Median	1.1
		Min - Max	1.0 - 1.2
Hemophilia severity	Mild	n	1
		Mean (SD)	1.20 (NE)
		Q1 - Q3	1.20 - 1.20
		Median	1.2
		Min - Max	1.2 - 1.2
	Moderate	n	1
		Mean (SD)	1.00 (NE)

		Q1 - Q3	1.00 - 1.00
		Median	1
		Min - Max	1.0 - 1.0
Current prophylactic/episodic status			
All	n/a	n	72
		Prophylactic	37 (51.4%)
		Episodic	35 (48.6%)
Hemophilia severity	Mild	n	21
		Prophylactic	9 (42.9%)
		Episodic	12 (57.1%)
	Moderate	n	51
		Prophylactic	28 (54.9%)
		Episodic	23 (45.1%)
Reason for being on an episodic treatment regimen*			
All	n/a	n	35
		Availability	6 (17.1%)
		Price/Reimbursement	4 (11.4%)
		Tolerability/Side Effects	0
		Efficacy	6 (17.1%)
		Frequency of Infusion/Half-Life	0
		Subject Request	11 (31.4%)
		Venous Access	5 (14.3%)
		Compliance Challenges with Regular Prophylaxis	4 (11.4%)
		Treatment Burden for Regular Prophylaxis	5 (14.3%)
		Treatment Accessibility	5 (14.3%)
		Other	7 (20.0%)
Hemophilia severity	Mild	n	12
		Availability	3 (25.0%)
		Price/Reimbursement	1 ( 8.3%)
		Tolerability/Side Effects	0
		Efficacy	1 ( 8.3%)
		Frequency of Infusion/Half-Life	0
		Subject Request	4 (33.3%)
		Venous Access	2 (16.7%)
		Compliance Challenges with Regular Prophylaxis	1 ( 8.3%)



		Treatment Burden for Regular Prophylaxis	1 ( 8.3%)
		Treatment Accessibility	3 (25.0%)
		Other	2 (16.7%)
	Moderate	n	23
		Availability	3 (13.0%)
		Price/Reimbursement	3 (13.0%)
		Tolerability/Side Effects	0
		Efficacy	5 (21.7%)
		Frequency of Infusion/Half-Life	0
		Subject Request	7 (30.4%)
		Venous Access	3 (13.0%)
		Compliance Challenges with Regular Prophylaxis	3 (13.0%)
		Treatment Burden for Regular Prophylaxis	4 (17.4%)
		Treatment Accessibility	2 ( 8.7%)
		Other	5 (21.7%)
Reason why patient warrant prophylaxis*			
All	n/a	n	72
		History of Frequent Bleeding	41 (56.9%)
		History of Frequent Joint Bleeding	32 (44.4%)
		History of Severe Bleeding	15 (20.8%)
		Prevention of Traumatic Bleeds	9 (12.5%)
		Other	5 ( 6.9%)
Hemophilia severity	Mild	n	21
		History of Frequent Bleeding	12 (57.1%)
		History of Frequent Joint Bleeding	7 (33.3%)
		History of Severe Bleeding	5 (23.8%)
		Prevention of Traumatic Bleeds	4 (19.0%)
		Other	1 ( 4.8%)
	Moderate	n	51
		History of Frequent Bleeding	29 (56.9%)
		History of Frequent Joint Bleeding	25 (49.0%)
		History of Severe Bleeding	10 (19.6%)
		Prevention of Traumatic Bleeds	5 ( 9.8%)
		Other	4 ( 7.8%)
Number of bleeds per year prior to study entry/regular prophylaxis			

All	n/a	n	24
		Mean (SD)	8.42 (12.55)
		Q1 - Q3	2.00 - 8.00
		Median	4.5
		Min - Max	0.0 - 60.0
Hemophilia severity	Mild	n	9
		Mean (SD)	6.44 (6.77)
		Q1 - Q3	1.00 - 6.00
		Median	5
		Min - Max	0.0 - 20.0
	Moderate	n	15
		Mean (SD)	9.60 (15.11)
		Q1 - Q3	2.00 - 9.00
		Median	4
		Min - Max	1.0 - 60.0
Number of joint bleeds per year prior to study entry/regular prophylaxis			
All	n/a	n	17
		Mean (SD)	11.94 (28.43)
		Q1 - Q3	2.00 - 8.00
		Median	3
		Min - Max	0.0 - 120.0
Hemophilia severity	Mild	n	5
		Mean (SD)	26.60 (52.30)
		Q1 - Q3	1.00 - 8.00
		Median	4
		Min - Max	0.0 - 120.0
	Moderate	n	12
		Mean (SD)	5.83 (6.52)
		Q1 - Q3	2.00 - 8.00
		Median	3
		Min - Max	1.0 - 24.0
Location of severe bleeding (reason why patient warrant prophylaxis)*			
All	n/a	n	15
		Joint Bleed	9 (60.0%)
		Muscle Bleed	4 (26.7%)

		Other Bleed	4 (26.7%)
Hemophilia severity	Mild	n	5
		Joint Bleed	2 (40.0%)
		Muscle Bleed	3 (60.0%)
		Other Bleed	1 (20.0%)
	Moderate	n	10
		Joint Bleed	7 (70.0%)
		Muscle Bleed	1 (10.0%)
		Other Bleed	3 (30.0%)
Reason for being on a prophylactic treatment regimen*			
All	n/a	n	37
		History of Frequent Bleeding	24 (64.9%)
		History of Joint Bleeding	15 (40.5%)
		History of Severe Bleeding	14 (37.8%)
		Prevention of Traumatic Bleeds	4 (10.8%)
		Other	1 ( 2.7%)
Hemophilia severity	Mild	n	9
		History of Frequent Bleeding	5 (55.6%)
		History of Joint Bleeding	3 (33.3%)
		History of Severe Bleeding	5 (55.6%)
		Prevention of Traumatic Bleeds	2 (22.2%)
	Moderate	n	28
		History of Frequent Bleeding	19 (67.9%)
		History of Joint Bleeding	12 (42.9%)
		History of Severe Bleeding	9 (32.1%)
		Prevention of Traumatic Bleeds	2 ( 7.1%)
		Other	1 ( 3.6%)
Number of bleeds per year prior to prophylaxis use			
All	n/a	n	12
		Mean (SD)	6.67 (4.72)
		Q1 - Q3	1.50 - 10.00
		Median	6.5
		Min - Max	1.0 - 15.0
Hemophilia severity	Mild	n	3
		Mean (SD)	9.00 (5.20)

		Q1 - Q3	6.00 - 15.00
		Median	6
		Min - Max	6.0 - 15.0
	Moderate	n	9
		Mean (SD)	5.89 (4.59)
		Q1 - Q3	1.00 - 10.00
		Median	7
		Min - Max	1.0 - 12.0
Number of joint bleeds per year prior to prophylaxis use			
All	n/a	n	7
		Mean (SD)	20.00 (44.16)
		Q1 - Q3	2.00 - 8.00
		Median	3
		Min - Max	1.0 - 120.0
Hemophilia severity	Mild	n	3
		Mean (SD)	44.00 (65.85)
		Q1 - Q3	4.00 - 120.00
		Median	8
		Min - Max	4.0 - 120.0
	Moderate	n	4
		Mean (SD)	2.00 (0.82)
		Q1 - Q3	1.50 - 2.50
		Median	2
		Min - Max	1.0 - 3.0
Location of severe bleeding (reason for being on a prophylactic treatment regimen)*			
All	n/a	n	14
		Joint Bleed	9 (64.3%)
		Muscle Bleed	4 (28.6%)
		Other Bleed	4 (28.6%)
Hemophilia severity	Mild	n	5
		Joint Bleed	3 (60.0%)
		Muscle Bleed	2 (40.0%)
		Other Bleed	1 (20.0%)
	Moderate	n	9
		Joint Bleed	6 (66.7%)

		Muscle Bleed	2 (22.2%)
		Other Bleed	3 (33.3%)
Prior episodic treatment in the last 24 weeks*			
All	n/a	n	40
		Factor VIII	35 (87.5%)
		Factor VIII long acting	6 (15.0%)
		Desmopressin (DDAVP)	1 ( 2.5%)
		Aminocaproic acid	0
		Tranexamic acid	3 ( 7.5%)
Hemophilia severity	Mild	n	15
		Factor VIII	11 (73.3%)
		Factor VIII long acting	3 (20.0%)
		Desmopressin (DDAVP)	1 ( 6.7%)
		Aminocaproic acid	0
		Tranexamic acid	2 (13.3%)
	Moderate	n	25
		Factor VIII	24 (96.0%)
		Factor VIII long acting	3 (12.0%)
		Desmopressin (DDAVP)	0
		Aminocaproic acid	0
		Tranexamic acid	1 ( 4.0%)
Prior prophylactic treatment in the last 24 weeks*			
All	n/a	n	38
		Factor VIII	22 (57.9%)
		Factor VIII long acting	16 (42.1%)
Hemophilia severity	Mild	n	10
		Factor VIII	5 (50.0%)
		Factor VIII long acting	5 (50.0%)
	Moderate	n	28
		Factor VIII	17 (60.7%)
		Factor VIII long acting	11 (39.3%)
Number of bleeds in the past 24 weeks			
All	n/a	n	72
		Mean (SD)	4.7 (13.2)

		Median	2
		Q1 - Q3	0.0 - 4.5
		Min - Max	0 - 96
Hemophilia severity	Mild	n	21
		Mean (SD)	9.3 (23.7)
		Median	1
		Q1 - Q3	0.0 - 5.0
		Min - Max	0 - 96
	Moderate	n	51
		Mean (SD)	2.7 (3.1)
		Median	2
		Q1 - Q3	0.0 - 4.0
		Min - Max	0 - 14
Number of bleeds in the past 24 weeks (category)			
All	n/a	<9	67 (93.1%)
		>=9	5 ( 6.9%)
Hemophilia severity	Mild	<9	18 (85.7%)
		>=9	3 (14.3%)
	Moderate	<9	49 (96.1%)
		>=9	2 ( 3.9%)
Number of target joints prior to study entry			
All	n/a	n	72
		Mean (SD)	0.6 (1.2)
		Median	0
		Q1 - Q3	0.0 - 1.0
		Min - Max	0 - 8
Hemophilia severity	Mild	n	21
		Mean (SD)	0.4 (0.7)
		Median	0
		Q1 - Q3	0.0 - 1.0
		Min - Max	0 - 2
	Moderate	n	51
		Mean (SD)	0.7 (1.3)
		Median	0
		Q1 - Q3	0.0 - 1.0

		Min - Max	0 - 8
Number of target joints prior to study entry (category 1)			
All	n/a	No target joint	48 (66.7%)
		Any target joint(s)	24 (33.3%)
Hemophilia severity	Mild	No target joint	15 (71.4%)
		Any target joint(s)	6 (28.6%)
	Moderate	No target joint	33 (64.7%)
		Any target joint(s)	18 (35.3%)
Number of target joints prior to study entry (category 2)			
All	n/a	1 joint	13 (54.2%)
		>1 joints	11 (45.8%)
Hemophilia severity	Mild	1 joint	4 (66.7%)
		>1 joints	2 (33.3%)
	Moderate	1 joint	9 (50.0%)
		>1 joints	9 (50.0%)
Location of target joint(s) at study entry*			
All	n/a	n	24
		Left shoulder	1 ( 4.2%)
		Left elbow	3 (12.5%)
		Left wrist	0
		Left fingers/thumb	0
		Left hip	2 ( 8.3%)
		Left knee	7 (29.2%)
		Left ankle	4 (16.7%)
		Left sole/heel	0
		Left toes	0
		Right shoulder	0
		Right elbow	3 (12.5%)
		Right wrist	0
		Right fingers/thumb	0
		Right hip	2 ( 8.3%)
		Right knee	11 (45.8%)
		Right ankle	10 (41.7%)
		Right sole/heel	0

		Right toes	0
Hemophilia severity	Mild	n	6
		Left shoulder	0
		Left elbow	0
		Left wrist	0
		Left fingers/thumb	0
		Left hip	0
		Left knee	3 (50.0%)
		Left ankle	0
		Left sole/heel	0
		Left toes	0
		Right shoulder	0
		Right elbow	0
		Right wrist	0
		Right fingers/thumb	0
		Right hip	0
		Right knee	5 (83.3%)
		Right ankle	0
		Right sole/heel	0
		Right toes	0
	Moderate	n	18
		Left shoulder	1 ( 5.6%)
		Left elbow	3 (16.7%)
		Left wrist	0
		Left fingers/thumb	0
		Left hip	2 (11.1%)
		Left knee	4 (22.2%)
		Left ankle	4 (22.2%)
		Left sole/heel	0
		Left toes	0
		Right shoulder	0
		Right elbow	3 (16.7%)
		Right wrist	0
		Right fingers/thumb	0
		Right hip	2 (11.1%)
		Right knee	6 (33.3%)
		Right ankle	10 (55.6%)



		Right sole/heel	0
		Right toes	0
Number of non-target joints prior to study entry			
All	n/a	n	72
		Mean (SD)	0.3 (0.6)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 2
Hemophilia severity	Mild	n	21
		Mean (SD)	0.2 (0.5)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 2
	Moderate	n	51
		Mean (SD)	0.3 (0.7)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 2
Number of non-target joints prior to study entry (category)			
All	n/a	1 joint	5 (41.7%)
		>1 joints	7 (58.3%)
Hemophilia severity	Mild	1 joint	2 (66.7%)
		>1 joints	1 (33.3%)
	Moderate	1 joint	3 (33.3%)
		>1 joints	6 (66.7%)
Location of non-target joint(s) at study entry*			
All	n/a	n	12
		Left shoulder	1 ( 8.3%)
		Left elbow	0
		Left wrist	0
		Left fingers/thumb	1 ( 8.3%)
		Left hip	1 ( 8.3%)
		Left knee	5 (41.7%)
		Left ankle	4 (33.3%)

		Left sole/heel	0
		Left toes	0
		Right shoulder	0
		Right elbow	0
		Right wrist	1 ( 8.3%)
		Right fingers/thumb	1 ( 8.3%)
		Right hip	0
		Right knee	1 ( 8.3%)
		Right ankle	3 (25.0%)
		Right sole/heel	0
		Right toes	1 ( 8.3%)
Hemophilia severity	Mild	n	3
		Left shoulder	0
		Left elbow	0
		Left wrist	0
		Left fingers/thumb	0
		Left hip	0
		Left knee	2 (66.7%)
		Left ankle	0
		Left sole/heel	0
		Left toes	0
		Right shoulder	0
		Right elbow	0
		Right wrist	0
		Right fingers/thumb	0
		Right hip	0
		Right knee	1 (33.3%)
		Right ankle	1 (33.3%)
		Right sole/heel	0
		Right toes	0
	Moderate	n	9
		Left shoulder	1 (11.1%)
		Left elbow	0
		Left wrist	0
		Left fingers/thumb	1 (11.1%)
		Left hip	1 (11.1%)
		Left knee	3 (33.3%)

		Left ankle	4 (44.4%)
		Left sole/heel	0
		Left toes	0
		Right shoulder	0
		Right elbow	0
		Right wrist	1 (11.1%)
		Right fingers/thumb	1 (11.1%)
		Right hip	0
		Right knee	0
		Right ankle	2 (22.2%)
		Right sole/heel	0
		Right toes	1 (11.1%)
Number of muscle locations prior to study entry			
All	n/a	n	72
		Mean (SD)	0.2 (0.5)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 2
Hemophilia severity	Mild	n	21
		Mean (SD)	0.1 (0.3)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 1
	Moderate	n	51
		Mean (SD)	0.2 (0.6)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 2
Number of muscle locations prior to study entry (category)			
All	n/a	1 muscle	8 (72.7%)
		>1 muscles	3 (27.3%)
Hemophilia severity	Mild	1 muscle	2 ( 100%)
		>1 muscles	0
	Moderate	1 muscle	6 (66.7%)
		>1 muscles	3 (33.3%)

Location of muscle bleeds at study entry*			
All	n/a	n	11
		Left upper arm	1 ( 9.1%)
		Left forearm	0
		Left chest	0
		Left upper abdomen	0
		Left lower abdomen	1 ( 9.1%)
		Left thigh	2 (18.2%)
		Left shin	0
		Left upper back	0
		Left middle back	0
		Left lower back	0
		Left buttock	1 ( 9.1%)
		Left hamstring	1 ( 9.1%)
		Left calf	2 (18.2%)
		Right upper arm	0
		Right forearm	1 ( 9.1%)
		Right chest	0
		Right upper abdomen	0
		Right lower abdomen	0
		Right thigh	3 (27.3%)
		Right shin	1 ( 9.1%)
		Right upper back	0
		Right middle back	0
		Right lower back	0
		Right buttock	1 ( 9.1%)
		Right hamstring	0
		Right calf	0
		Back of left upper arm	0
		Back of left forearm	0
		Back of right upper arm	0
		Back of right forearm	0
Hemophilia severity	Mild	n	2
		Left upper arm	0
		Left forearm	0
		Left chest	0

		Left upper abdomen	0
		Left lower abdomen	0
		Left thigh	0
		Left shin	0
		Left upper back	0
		Left middle back	0
		Left lower back	0
		Left buttock	0
		Left hamstring	0
		Left calf	1 (50.0%)
		Right upper arm	0
		Right forearm	0
		Right chest	0
		Right upper abdomen	0
		Right lower abdomen	0
		Right thigh	1 (50.0%)
		Right shin	0
		Right upper back	0
		Right middle back	0
		Right lower back	0
		Right buttock	0
		Right hamstring	0
		Right calf	0
		Back of left upper arm	0
		Back of left forearm	0
		Back of right upper arm	0
		Back of right forearm	0
	Moderate	n	9
		Left upper arm	1 (11.1%)
		Left forearm	0
		Left chest	0
		Left upper abdomen	0
		Left lower abdomen	1 (11.1%)
		Left thigh	2 (22.2%)
		Left shin	0
		Left upper back	0
		Left middle back	0

		Left lower back	0
		Left buttock	1 (11.1%)
		Left hamstring	1 (11.1%)
		Left calf	1 (11.1%)
		Right upper arm	0
		Right forearm	1 (11.1%)
		Right chest	0
		Right upper abdomen	0
		Right lower abdomen	0
		Right thigh	2 (22.2%)
		Right shin	1 (11.1%)
		Right upper back	0
		Right middle back	0
		Right lower back	0
		Right buttock	1 (11.1%)
		Right hamstring	0
		Right calf	0
		Back of left upper arm	0
		Back of left forearm	0
		Back of right upper arm	0
		Back of right forearm	0
Number of other locations prior to study entry			
All	n/a	n	72
		Mean (SD)	0.5 (1.1)
		Median	0
		Q1 - Q3	0.0 - 1.0
		Min - Max	0 - 6
Hemophilia severity	Mild	n	21
		Mean (SD)	0.3 (0.9)
		Median	0
		Q1 - Q3	0.0 - 0.0
		Min - Max	0 - 4
	Moderate	n	51
		Mean (SD)	0.6 (1.2)
		Median	0
		Q1 - Q3	0.0 - 1.0

		Min - Max	0 - 6
Number of other locations prior to study entry (category)			
All	n/a	1 other location	13 (61.9%)
		>1 other locations	8 (38.1%)
Hemophilia severity	Mild	1 other location	2 (66.7%)
		>1 other locations	1 (33.3%)
	Moderate	1 other location	11 (61.1%)
		>1 other locations	7 (38.9%)
Location of other bleeds at study entry*			
All	n/a	n	21
		Forehead	4 (19.0%)
		Left cheek/face	0
		Right cheek/face	0
		Nose	3 (14.3%)
		Mouth	6 (28.6%)
		Throat	0
		Left Eye	0
		Right Eye	0
		Left ear	1 ( 4.8%)
		Right ear	0
		Back of the head	1 ( 4.8%)
		Top of the head	0
		Neck	0
		Left chest	0
		Right chest	0
		Left upper abdomen	1 ( 4.8%)
		Right upper abdomen	2 ( 9.5%)
		Left lower abdomen	1 ( 4.8%)
		Right lower abdomen	1 ( 4.8%)
		Left side	0
		Right side	0
		Genitalia	1 ( 4.8%)
		Left upper back	0
		Right upper back	0
		Left middle back	0

	Right middle back	0
	Left lower back	0
	Right lower back	0
	Left buttock	0
	Right buttock	0
	Left upper arm	0
	Left forearm	0
	Left wrist	1 ( 4.8%)
	Left palm	0
	Left fingers/thumb	3 (14.3%)
	Right upper arm	1 ( 4.8%)
	Right forearm	1 ( 4.8%)
	Right wrist	0
	Right palm	0
	Right fingers/thumb	2 ( 9.5%)
	Left hip	0
	Left thigh	2 ( 9.5%)
	Left knee	0
	Left shin	1 ( 4.8%)
	Left ankle	0
	Left foot	1 ( 4.8%)
	Left toes	0
	Right hip	2 ( 9.5%)
	Right thigh	1 ( 4.8%)
	Right knee	0
	Right shin	0
	Right ankle	0
	Right foot	1 ( 4.8%)
	Right toes	0
	Left hamstring	0
	Back of left knee	1 ( 4.8%)
	Left calf	0
	Left sole/heel	0
	Right hamstring	0
	Back of right knee	0
	Right calf	0
	Right sole/heel	0



		Left shoulder	0
		Back of left upper arm	0
		Left elbow	0
		Back of left forearm	0
		Back of left hand	1 ( 4.8%)
		Right shoulder	0
		Back of right upper arm	0
		Right elbow	0
		Back of right forearm	0
		Back of right hand	0
Hemophilia severity	Mild	n	3
		Forehead	0
		Left cheek/face	0
		Right cheek/face	0
		Nose	2 (66.7%)
		Mouth	1 (33.3%)
		Throat	0
		Left Eye	0
		Right Eye	0
		Left ear	1 (33.3%)
		Right ear	0
		Back of the head	0
		Top of the head	0
		Neck	0
		Left chest	0
		Right chest	0
		Left upper abdomen	0
		Right upper abdomen	0
		Left lower abdomen	0
		Right lower abdomen	0
		Left side	0
		Right side	0
		Genitalia	0
		Left upper back	0
		Right upper back	0
		Left middle back	0
		Right middle back	0

	Left lower back	0
	Right lower back	0
	Left buttock	0
	Right buttock	0
	Left upper arm	0
	Left forearm	0
	Left wrist	0
	Left palm	0
	Left fingers/thumb	0
	Right upper arm	0
	Right forearm	1 (33.3%)
	Right wrist	0
	Right palm	0
	Right fingers/thumb	0
	Left hip	0
	Left thigh	1 (33.3%)
	Left knee	0
	Left shin	0
	Left ankle	0
	Left foot	0
	Left toes	0
	Right hip	0
	Right thigh	0
	Right knee	0
	Right shin	0
	Right ankle	0
	Right foot	0
	Right toes	0
	Left hamstring	0
	Back of left knee	0
	Left calf	0
	Left sole/heel	0
	Right hamstring	0
	Back of right knee	0
	Right calf	0
	Right sole/heel	0
	Left shoulder	0

		Back of left upper arm	0
		Left elbow	0
		Back of left forearm	0
		Back of left hand	0
		Right shoulder	0
		Back of right upper arm	0
		Right elbow	0
		Back of right forearm	0
		Back of right hand	0
	Moderate	n	18
		Forehead	4 (22.2%)
		Left cheek/face	0
		Right cheek/face	0
		Nose	1 ( 5.6%)
		Mouth	5 (27.8%)
		Throat	0
		Left Eye	0
		Right Eye	0
		Left ear	0
		Right ear	0
		Back of the head	1 ( 5.6%)
		Top of the head	0
		Neck	0
		Left chest	0
		Right chest	0
		Left upper abdomen	1 ( 5.6%)
		Right upper abdomen	2 (11.1%)
		Left lower abdomen	1 ( 5.6%)
		Right lower abdomen	1 ( 5.6%)
		Left side	0
		Right side	0
		Genitalia	1 ( 5.6%)
		Left upper back	0
		Right upper back	0
		Left middle back	0
		Right middle back	0
		Left lower back	0

	Right lower back	0
	Left buttock	0
	Right buttock	0
	Left upper arm	0
	Left forearm	0
	Left wrist	1 ( 5.6%)
	Left palm	0
	Left fingers/thumb	3 (16.7%)
	Right upper arm	1 ( 5.6%)
	Right forearm	0
	Right wrist	0
	Right palm	0
	Right fingers/thumb	2 (11.1%)
	Left hip	0
	Left thigh	1 ( 5.6%)
	Left knee	0
	Left shin	1 ( 5.6%)
	Left ankle	0
	Left foot	1 ( 5.6%)
	Left toes	0
	Right hip	2 (11.1%)
	Right thigh	1 ( 5.6%)
	Right knee	0
	Right shin	0
	Right ankle	0
	Right foot	1 ( 5.6%)
	Right toes	0
	Left hamstring	0
	Back of left knee	1 ( 5.6%)
	Left calf	0
	Left sole/heel	0
	Right hamstring	0
	Back of right knee	0
	Right calf	0
	Right sole/heel	0
	Left shoulder	0
	Back of left upper arm	0

	Left elbow	0
	Back of left forearm	0
	Back of left hand	1 ( 5.6%)
	Right shoulder	0
	Back of right upper arm	0
	Right elbow	0
	Back of right forearm	0
	Back of right hand	0

\* Multiple answers are possible.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/oth\_dm.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/oth\_dm\_DEC21\_TRT\_SG.xls

09MAR2022 15:37

POPULATION: All Treated Patients, Intent-to-Treat Patients

ENDPOINT: --

MODEL: --

STUDY: BO41423

Median Follow-up Time

		Emicizumab (N=72)				
		Follow-up Time (months) *				
Name	Level	n	Mean	Median	Minimum	Maximum
All	n/a	72	12.95	12.80	2.0	20.7
Hemophilia severity	Mild	21	11.33	11.89	2.0	20.7
	Moderate	51	13.61	13.47	10.0	20.7

\* Calculated from enrollment date to minimum of death, lost to follow-up, withdrawal of consent and cut-off date.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/oth\_fut.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/oth\_fut\_DEC21\_TRT\_ITT\_SG.xls

09MAR2022 15:43

POPULATION: All Treated Patients, Safety Patients

ENDPOINT: --

MODEL: --

STUDY: BO41423

Median Follow-up Time

		Emicizumab (N=72)				
		Follow-up Time (months)*				
Name	Level	n	Mean	Median	Minimum	Maximum
All	n/a	72	12.94	12.80	2.0	20.7
Hemophilia severity	Mild	21	11.33	11.86	2.0	20.7
	Moderate	51	13.60	13.44	9.9	20.7

\* Calculated from treatment start date to minimum of Emicizumab discontinuation date + 24 weeks + 7 days, death, lost to follow-up, withdrawal of consent and cut-off date.  
Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/oth\_fut.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/oth\_fut\_DEC21\_TRT\_SAF\_SG.xls

09MAR2022 15:43

POPULATION: All Treated Patients, PRO-Evaluable Patients

ENDPOINT: --

MODEL: --

STUDY: BO41423

Median Follow-up Time

		Emicizumab (N=70)				
		Follow-up Time (months) *				
Name	Level	n	Mean	Median	Minimum	Maximum
All	n/a	70	11.44	11.07	1.9	14.1
Hemophilia severity	Mild	20	10.01	11.07	1.9	14.1
	Moderate	50	12.00	11.09	8.3	14.1

\* Calculated from treatment start date to minimum of date of last PRO value, death, lost to follow-up, withdrawal of consent and cut-off date.  
Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/oth\_fut.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/oth\_fut\_DEC21\_TRT\_PRO\_SG.xls

09MAR2022 15:43



POPULATION: All Treated Patients

ENDPOINT: --

MODEL: --

STUDY: BO41423

Disposition of Patients

Status	Emicizumab (N=72)
Patients enrolled	72 ( 100%)
Patients treated	72 ( 100%)
Patients who discontinued prematurely prior to 1st emicizumab administration	0
Patients with duration of efficacy period <24 weeks	1 ( 1.4%)
Patients who completed 24 weeks in the study	71 (98.6%)
Patients with duration of efficacy period <52 weeks	15 (20.8%)
Patients who completed 52 weeks in the study	57 (79.2%)
Patients with dose up-titration	0
Patients who started safety follow-up	0
Patients who completed safety follow-up	0
Patients who discontinued from the study	3 ( 4.2%)
Withdrawal by subject	3 ( 100%)
Patients who discontinued from treatment	3 ( 4.2%)
Withdrawal by subject	3 ( 100%)
Patients who completed the study	0

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/oth\_ds.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/oth\_ds\_DEC21\_TRT.xls

09MAR2022 15:54

POPULATION: All Treated Patients  
 ENDPOINT: All Bleeds  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	24	33.3	48	66.7	2.28	1.67	3.12	2.33	0.35	7.75	1.02	0.00	3.11	0.0	21.0
Hemophilia severity	Mild	21	29.2	7	33.3	14	66.7	2.41	1.28	4.53	2.58	0.45	8.13	0.99	0.00	2.51	0.0	21.0
	Moderate	51	70.8	17	33.3	34	66.7	2.25	1.57	3.20	2.23	0.32	7.59	1.04	0.00	3.14	0.0	12.2

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLALL\_SG.xls  
 14MAR2022 13:13

POPULATION: All Treated Patients  
 ENDPOINT: Treated Bleeds  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	48	66.7	24	33.3	0.91	0.55	1.52	0.94	0.02	5.48	0.00	0.00	0.98	0.0	7.1
Hemophilia severity	Mild	21	29.2	13	61.9	8	38.1	0.79	0.35	1.79	0.98	0.02	5.54	0.00	0.00	0.98	0.0	6.1
	Moderate	51	70.8	35	68.6	16	31.4	0.94	0.50	1.78	0.93	0.02	5.45	0.00	0.00	0.98	0.0	7.1

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLTTRT\_SG.xls  
 14MAR2022 13:14

POPULATION: All Treated Patients  
 ENDPOINT: Treated Spontaneous Bleeds  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	59	81.9	13	18.1	0.20	0.11	0.33	0.27	0.00	4.23	0.00	0.00	0.00	0.0	6.1
Hemophilia severity	Mild	21	29.2	16	76.2	5	23.8	0.32	0.13	0.80	0.54	0.00	4.75	0.00	0.00	0.00	0.0	6.1
	Moderate	51	70.8	43	84.3	8	15.7	0.16	0.08	0.30	0.15	0.00	4.01	0.00	0.00	0.00	0.0	1.9

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLSPON\_SG.xls  
 14MAR2022 13:17

POPULATION: All Treated Patients  
 ENDPOINT: Treated Traumatic Bleeds  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	53	73.6	19	26.4	0.69	0.39	1.23	0.68	0.00	5.00	0.00	0.00	0.88	0.0	7.1
Hemophilia severity	Mild	21	29.2	15	71.4	6	28.6	0.42	0.18	0.97	0.45	0.00	4.57	0.00	0.00	0.86	0.0	3.2
	Moderate	51	70.8	38	74.5	13	25.5	0.78	0.38	1.63	0.77	0.01	5.17	0.00	0.00	0.89	0.0	7.1

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLTRM\_SG.xls  
 14MAR2022 13:20

POPULATION: All Treated Patients  
 ENDPOINT: Treated Bleeds because of Procedure/Surgery  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	65	90.3	7	9.7	0.16	0.07	0.39	0.16	0.00	4.02	0.00	0.00	0.00	0.0	2.8
Hemophilia severity	Mild	21	29.2	19	90.5	2	9.5	0.10	0.03	0.40	0.10	0.00	3.90	0.00	0.00	0.00	0.0	1.1
	Moderate	51	70.8	46	90.2	5	9.8	0.18	0.06	0.55	0.18	0.00	4.06	0.00	0.00	0.00	0.0	2.8

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLPROC\_SG.xls  
 14MAR2022 13:19

POPULATION: All Treated Patients  
 ENDPOINT: Treated Joint Bleeds  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	64	88.9	8	11.1	0.23	0.09	0.57	0.23	0.00	4.15	0.00	0.00	0.00	0.0	3.6
Hemophilia severity	Mild	21	29.2	18	85.7	3	14.3	0.26	0.07	0.99	0.25	0.00	4.20	0.00	0.00	0.00	0.0	3.2
	Moderate	51	70.8	46	90.2	5	9.8	0.22	0.07	0.71	0.22	0.00	4.13	0.00	0.00	0.00	0.0	3.6

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLJNT\_SG.xls  
 14MAR2022 13:16

POPULATION: All Treated Patients  
 ENDPOINT: Treated Target Joint Bleeds  
 MODEL: --  
 STUDY: BO41423  
 NB Regression Model-based ABR (efficacy)

		Emicizumab (N=72)																
Name	Level	Patients		Patients with Zero Bleeds		Patients with Bleeds		NB Regression Model-based Estimates			Summary Statistics of ABR							
		n	%	n	%	n	%	ABR	95% Lower CI for ABR*	95% Upper CI for ABR*	Mean	95% Lower CI for Mean**	95% Upper CI for Mean**	Median	Q1	Q3	Min	Max
All	n/a	72	100.0	68	94.4	4	5.6	0.11	0.03	0.40	0.11	0.00	3.92	0.00	0.00	0.00	0.0	3.2
Hemophilia severity	Mild	21	29.2	19	90.5	2	9.5	0.21	0.04	1.18	0.20	0.00	4.10	0.00	0.00	0.00	0.0	3.2
	Moderate	51	70.8	49	96.1	2	3.9	0.07	0.01	0.45	0.07	0.00	3.84	0.00	0.00	0.00	0.0	2.8

NB : negative binomial  
 \* 95% CI based on Wald Method.  
 \*\* 95% CI based on Poisson Exact Method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_abr.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_abr\_DEC21\_TRT\_BLTJ\_SG.xls  
 14MAR2022 13:18



POPULATION: All Treated Patients  
 ENDPOINT: Joint Health: Original Sum of Joint Totals (as reported)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=72)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	72	100.0	70	97.2	6.73	9.49	NE	NE
Week 25 Day 169	n/a	71	98.6	60	84.5	5.73	8.30	-1.25	2.86
Week 29 Day 197	n/a	70	97.2	3	4.3	0.00	0.00	0.00	0.00
Week 49 Day 337	n/a	67	93.1	61	91.0	5.18	7.79	-1.27	3.46
Week 61 Day 421	n/a	45	62.5	1	2.2	0.00	NE	-16.00	NE
Week 73 Day 505	n/a	13	18.1	2	15.4	8.50	0.71	-4.50	4.95
Patient Disposition	n/a	2	2.8	2	100.0	13.00	16.97	0.00	1.41
Hemophilia severity									
Baseline	Mild	21	29.2	21	100.0	8.10	11.17	NE	NE
	Moderate	51	70.8	49	96.1	6.14	8.74	NE	NE
Week 25 Day 169	Mild	20	27.8	19	95.0	6.00	9.15	-1.05	3.84
	Moderate	51	70.8	41	80.4	5.61	8.00	-1.35	2.32
Week 29 Day 197	Mild	19	26.4	0	0.0	NE	NE	NE	NE
	Moderate	51	70.8	3	5.9	0.00	0.00	0.00	0.00
Week 49 Day 337	Mild	17	23.6	14	82.4	5.29	8.40	-2.14	5.52
	Moderate	50	69.4	47	94.0	5.15	7.70	-1.00	2.55
Week 61 Day 421	Mild	6	8.3	1	16.7	0.00	NE	-16.00	NE
	Moderate	39	54.2	0	0.0	NE	NE	NE	NE
Week 73 Day 505	Mild	1	1.4	1	100.0	8.00	NE	-8.00	NE
	Moderate	12	16.7	1	8.3	9.00	NE	-1.00	NE
Patient Disposition	Mild	1	1.4	1	100.0	25.00	NE	1.00	NE
	Moderate	1	1.4	1	100.0	1.00	NE	-1.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRT\_JOINTS\_SG.xls

15MAR2022 16:43

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Original Sum of Joint Totals (as reported)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=72)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_JOINTS\_SG.pdf  
16MAR2022 15:26

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Original Sum of Joint Totals (as reported)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_JOINTS\_SG.pdf  
16MAR2022 15:26

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Original Sum of Joint Totals (as reported)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=51)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_JOINTS\_SG.pdf  
16MAR2022 15:26

POPULATION: All Treated Patients  
 ENDPOINT: Joint Health: Structural Component  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=72)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	72	100.0	70	97.2	2.93	4.09	NE	NE
Week 25 Day 169	n/a	71	98.6	60	84.5	2.38	3.44	-0.76	2.07
Week 29 Day 197	n/a	70	97.2	3	4.3	0.00	0.00	0.00	0.00
Week 49 Day 337	n/a	67	93.1	61	91.0	2.16	3.33	-0.75	2.54
Week 61 Day 421	n/a	45	62.5	0	0.0	NE	NE	NE	NE
Week 73 Day 505	n/a	13	18.1	2	15.4	3.50	0.71	-0.50	0.71
Patient Disposition	n/a	2	2.8	2	100.0	2.50	2.12	-3.00	2.83
Hemophilia severity									
Baseline	Mild	21	29.2	21	100.0	3.48	4.76	NE	NE
	Moderate	51	70.8	49	96.1	2.69	3.79	NE	NE
Week 25 Day 169	Mild	20	27.8	19	95.0	2.37	3.34	-0.79	2.57
	Moderate	51	70.8	41	80.4	2.39	3.53	-0.75	1.82
Week 29 Day 197	Mild	19	26.4	0	0.0	NE	NE	NE	NE
	Moderate	51	70.8	3	5.9	0.00	0.00	0.00	0.00
Week 49 Day 337	Mild	17	23.6	14	82.4	2.14	3.28	-1.43	3.52
	Moderate	50	69.4	47	94.0	2.17	3.38	-0.53	2.15
Week 61 Day 421	Mild	6	8.3	0	0.0	NE	NE	NE	NE
	Moderate	39	54.2	0	0.0	NE	NE	NE	NE
Week 73 Day 505	Mild	1	1.4	1	100.0	4.00	NE	-1.00	NE
	Moderate	12	16.7	1	8.3	3.00	NE	0.00	NE
Patient Disposition	Mild	1	1.4	1	100.0	4.00	NE	-5.00	NE
	Moderate	1	1.4	1	100.0	1.00	NE	-1.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRT\_STRUCT\_SG.xls

15MAR2022 16:55

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Structural Component**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=72)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_STRUCT\_SG.pdf  
16MAR2022 15:43

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Structural Component**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_STRUCT\_SG.pdf  
16MAR2022 15:43

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Structural Component**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=51)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_STRUCT\_SG.pdf  
16MAR2022 15:43



POPULATION: All Treated Patients  
 ENDPOINT: Joint Health: Functional Component  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=72)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	72	100.0	69	95.8	3.64	5.64	NE	NE
Week 25 Day 169	n/a	71	98.6	59	83.1	3.41	5.52	-0.61	1.29
Week 29 Day 197	n/a	70	97.2	3	4.3	0.00	0.00	0.00	0.00
Week 49 Day 337	n/a	67	93.1	59	88.1	3.12	5.13	-0.53	1.60
Week 61 Day 421	n/a	45	62.5	0	0.0	NE	NE	NE	NE
Week 73 Day 505	n/a	13	18.1	2	15.4	5.00	1.41	-4.00	4.24
Patient Disposition	n/a	2	2.8	2	100.0	10.50	14.85	0.00	NE
Hemophilia severity									
Baseline	Mild	21	29.2	20	95.2	4.10	6.46	NE	NE
	Moderate	51	70.8	49	96.1	3.45	5.33	NE	NE
Week 25 Day 169	Mild	20	27.8	18	90.0	3.83	6.63	-0.65	1.69
	Moderate	51	70.8	41	80.4	3.22	5.04	-0.60	1.10
Week 29 Day 197	Mild	19	26.4	0	0.0	NE	NE	NE	NE
	Moderate	51	70.8	3	5.9	0.00	0.00	0.00	0.00
Week 49 Day 337	Mild	17	23.6	13	76.5	3.38	5.87	-0.77	2.39
	Moderate	50	69.4	46	92.0	3.04	4.97	-0.47	1.32
Week 61 Day 421	Mild	6	8.3	0	0.0	NE	NE	NE	NE
	Moderate	39	54.2	0	0.0	NE	NE	NE	NE
Week 73 Day 505	Mild	1	1.4	1	100.0	4.00	NE	-7.00	NE
	Moderate	12	16.7	1	8.3	6.00	NE	-1.00	NE
Patient Disposition	Mild	1	1.4	1	100.0	21.00	NE	NE	NE
	Moderate	1	1.4	1	100.0	0.00	NE	0.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRT\_FUNC\_SG.xls

15MAR2022 16:54

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Functional Component**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=72)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_FUNC\_SG.pdf  
16MAR2022 15:40

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Functional Component**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_FUNC\_SG.pdf  
16MAR2022 15:40

**POPULATION: All Treated Patients**  
**ENDPOINT: Joint Health: Functional Component**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=51)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRT\_FUNC\_SG.pdf  
16MAR2022 15:40

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: EQ-5D-5L: Visual Analog Scale  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=56)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	56	100.0	50	89.3	76.14	18.82	NE	NE
Week 1 Day 1	n/a	56	100.0	4	7.1	90.25	6.85	NE	NE
Week 13 Day 85	n/a	56	100.0	51	91.1	82.04	17.89	4.39	11.62
Week 25 Day 169	n/a	55	98.2	53	96.4	80.04	16.39	2.71	10.99
Week 37 Day 253	n/a	53	94.6	49	92.5	81.65	16.14	3.39	13.26
Week 49 Day 337	n/a	51	91.1	46	90.2	77.93	17.01	1.76	10.87
Week 61 Day 421	n/a	32	57.1	15	46.9	83.33	19.63	5.85	7.02
Week 73 Day 505	n/a	9	16.1	2	22.2	94.00	1.41	NE	NE
Week 85 Day 589	n/a	2	3.6	2	100.0	80.00	14.14	NE	NE
Patient Disposition	n/a	2	3.6	2	100.0	70.00	14.14	-5.50	6.36
Hemophilia severity									
Baseline	Mild	19	33.9	16	84.2	72.50	14.19	NE	NE
	Moderate	37	66.1	34	91.9	77.85	20.61	NE	NE
Week 1 Day 1	Mild	19	33.9	2	10.5	94.50	7.78	NE	NE
	Moderate	37	66.1	2	5.4	86.00	2.83	NE	NE
Week 13 Day 85	Mild	19	33.9	18	94.7	83.44	16.13	8.47	11.71
	Moderate	37	66.1	33	89.2	81.27	18.98	2.42	11.24
Week 25 Day 169	Mild	18	32.1	17	94.4	78.41	15.93	3.86	12.48
	Moderate	37	66.1	36	97.3	80.81	16.77	2.24	10.48
Week 37 Day 253	Mild	16	28.6	14	87.5	82.79	19.53	5.09	11.72
	Moderate	37	66.1	35	94.6	81.20	14.87	2.82	13.86
Week 49 Day 337	Mild	15	26.8	14	93.3	74.57	19.33	2.83	8.27
	Moderate	36	64.3	32	88.9	79.41	16.00	1.33	11.85
Week 61 Day 421	Mild	6	10.7	4	66.7	84.00	17.76	0.33	9.07
	Moderate	26	46.4	11	42.3	83.09	21.08	7.50	5.85
Week 73 Day 505	Mild	1	1.8	1	100.0	93.00	NE	NE	NE
	Moderate	8	14.3	1	12.5	95.00	NE	NE	NE
Week 85 Day 589	Mild	1	1.8	1	100.0	70.00	NE	NE	NE
	Moderate	1	1.8	1	100.0	90.00	NE	NE	NE
Patient Disposition	Mild	1	1.8	1	100.0	60.00	NE	-10.00	NE
	Moderate	1	1.8	1	100.0	80.00	NE	-1.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 12 years


**ENDPOINT:** EQ-5D-5L: Visual Analog Scale

**MODEL:** --

**STUDY:** BO41423

**Mean Plot**

All (N=56)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE12\_VAS\_SG.pdf  
16MAR2022 15:20

**POPULATION:** Treated Patients Aged >= 12 years


**ENDPOINT:** EQ-5D-5L: Visual Analog Scale

**MODEL:** --

**STUDY:** BO41423

**Mean Plot**

Hemophilia severity: Mild (N=19)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE12\_VAS\_SG.pdf  
16MAR2022 15:20

**POPULATION: Treated Patients Aged >= 12 years**


**ENDPOINT: EQ-5D-5L: Visual Analog Scale**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Moderate (N=37)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE12\_VAS\_SG.pdf  
16MAR2022 15:20



POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Steps Count (cts)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	6440.72	2617.32	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	6201.81	2369.36	43.96	1845.72	-475.16	563.07	64.15	-1068.73	1671.77	-6002.8	4147.7
Week 25	n/a		65	97.0	52	80.0	6335.68	2614.68	119.07	2977.41	-727.10	965.24	234.33	-848.23	1952.10	-8441.1	6047.5
Week 37	n/a		59	88.1	53	89.8	6927.03	2485.13	766.59	3189.26	-130.40	1663.58	340.33	-743.86	2378.77	-9166.1	9744.4
Week 49	n/a		52	77.6	48	92.3	7502.32	2147.36	1216.18	2439.63	499.87	1932.48	1302.75	-247.33	3009.47	-5104.4	7752.8
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	5739.05	2652.17	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	6758.14	2570.10	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	5745.51	2263.02	337.07	1453.48	-502.15	1176.28	109.04	-429.85	945.88	-2195.9	3032.9
	Moderate		46	68.7	38	82.6	6381.93	2415.42	-66.95	1980.55	-727.30	593.40	11.21	-1068.73	1671.77	-6002.8	4147.7
Week 25	Mild		19	28.4	14	73.7	6621.81	3029.04	1316.78	2431.98	-152.85	2786.41	768.06	-612.45	3448.81	-2343.6	6047.5
	Moderate		46	68.7	38	82.6	6230.27	2481.39	-301.74	3065.07	-1323.69	720.20	-189.64	-1090.71	1396.97	-8441.1	5835.8
Week 37	Mild		15	22.4	13	86.7	6706.44	2472.44	1379.23	2551.54	-241.94	3000.40	599.40	119.40	2790.11	-2666.7	7534.9
	Moderate		44	65.7	40	90.9	6998.73	2516.36	578.09	3368.06	-513.71	1669.88	192.21	-798.25	2377.85	-9166.1	9744.4
Week 49	Mild		13	19.4	12	92.3	6698.63	2609.39	1392.24	2320.86	-82.37	2866.85	1033.06	-273.04	3227.77	-2686.3	4808.1
	Moderate		39	58.2	36	92.3	7770.22	1938.27	1155.81	2509.00	293.94	2017.68	1302.75	-247.33	2651.08	-5104.4	7752.8

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_DSCM\_SG.xls

16MAR2022 12:46

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Steps Count (cts)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGES\_DSCM\_SG.pdf  
16MAR2022 15:43

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Steps Count (cts)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGES\_DSCM\_SG.pdf  
16MAR2022 15:43

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Steps Count (cts)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_DSCM\_SG.pdf  
16MAR2022 15:43

POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Mean Activity Counts over 14 Days (cts/min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean


		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	2639.58	785.89	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	2638.06	748.59	-43.73	404.33	-157.44	69.99	-3.81	-243.72	146.99	-1165.6	930.7
Week 25	n/a		65	97.0	52	80.0	2699.49	813.67	23.04	615.14	-151.78	197.87	47.40	-153.14	356.40	-2284.9	1003.7
Week 37	n/a		59	88.1	53	89.8	2728.22	735.46	97.36	614.76	-75.54	270.26	91.04	-128.33	450.41	-2014.0	1759.4
Week 49	n/a		52	77.6	48	92.3	2684.90	733.85	64.96	466.95	-72.15	202.06	70.43	-125.25	367.89	-1299.5	1131.4
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	2394.59	519.34	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	2750.41	863.16	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	2480.71	618.26	41.79	439.01	-211.69	295.27	61.30	-256.70	146.99	-738.1	930.7
	Moderate		46	68.7	38	82.6	2700.17	793.05	-76.08	391.84	-206.73	54.56	-23.02	-243.44	138.53	-1165.6	608.5
Week 25	Mild		19	28.4	14	73.7	2689.91	730.40	370.18	425.79	112.87	627.48	292.17	35.83	786.79	-153.1	1003.7
	Moderate		46	68.7	38	82.6	2703.01	851.52	-98.92	629.13	-308.68	110.84	1.90	-347.98	252.96	-2284.9	828.1
Week 37	Mild		15	22.4	13	86.7	2550.11	458.48	280.61	491.59	-31.73	592.95	270.06	-17.20	560.18	-642.2	1278.8
	Moderate		44	65.7	40	90.9	2786.11	801.57	40.98	643.00	-167.46	249.41	-23.10	-203.63	254.34	-2014.0	1759.4
Week 49	Mild		13	19.4	12	92.3	2361.80	257.72	110.88	428.17	-161.16	382.93	129.93	-47.13	348.06	-705.6	804.4
	Moderate		39	58.2	36	92.3	2792.60	809.06	49.21	484.45	-117.20	215.62	70.43	-152.80	367.89	-1299.5	1131.4

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_MACTM\_SG.xls  
 16MAR2022 12:49

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Mean Activity Counts over 14 Days (cts/min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_MACTM\_SG.pdf  
16MAR2022 15:47

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Mean Activity Counts over 14 Days (cts/min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_MACTM\_SG.pdf  
16MAR2022 15:47

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Mean Activity Counts over 14 Days (cts/min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_MACTM\_SG.pdf  
16MAR2022 15:47



POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Light Physical Activity (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	705.46	78.66	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	716.17	75.67	20.90	78.90	-1.29	43.09	15.44	-22.01	53.16	-107.0	348.4
Week 25	n/a		65	97.0	52	80.0	694.65	81.52	0.22	80.27	-22.59	23.03	-10.33	-46.45	33.24	-171.3	261.9
Week 37	n/a		59	88.1	53	89.8	707.37	88.71	6.38	103.40	-22.70	35.46	-13.68	-68.02	58.43	-135.2	376.9
Week 49	n/a		52	77.6	48	92.3	723.21	68.52	18.28	92.02	-8.74	45.30	11.16	-36.99	72.60	-168.7	305.4
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	696.64	75.88	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	709.45	80.47	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	725.07	75.06	46.26	100.81	-11.94	104.46	37.25	-12.84	70.62	-75.5	348.4
	Moderate		46	68.7	38	82.6	712.65	76.62	11.30	68.06	-11.39	33.99	12.63	-22.01	37.39	-107.0	166.9
Week 25	Mild		19	28.4	14	73.7	687.31	63.14	-0.51	73.95	-45.20	44.18	-9.00	-46.45	13.28	-114.1	170.9
	Moderate		46	68.7	38	82.6	697.35	87.93	0.48	83.34	-27.31	28.27	-14.49	-38.89	47.05	-171.3	261.9
Week 37	Mild		15	22.4	13	86.7	709.85	85.63	21.79	117.22	-52.69	96.27	3.73	-56.41	41.41	-90.4	347.2
	Moderate		44	65.7	40	90.9	706.57	90.74	1.64	99.97	-30.77	34.05	-17.97	-68.02	61.46	-135.2	376.9
Week 49	Mild		13	19.4	12	92.3	735.73	65.98	43.54	106.14	-23.90	110.97	52.95	-27.48	80.61	-116.0	283.0
	Moderate		39	58.2	36	92.3	719.04	69.75	9.62	86.65	-20.15	39.38	6.98	-36.99	54.01	-168.7	305.4

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_LGPAM\_SG.xls

16MAR2022 12:47

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Light Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_LGPAM\_SG.pdf  
16MAR2022 15:44

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Light Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_LGPAM\_SG.pdf  
16MAR2022 15:44

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Light Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_LGPAM\_SG.pdf  
16MAR2022 15:44

POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Locomotion (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	37.71	18.41	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	34.08	19.32	-2.88	10.52	-5.84	0.08	-1.91	-9.31	5.67	-29.6	21.9
Week 25	n/a		65	97.0	52	80.0	36.32	22.04	-1.33	17.39	-6.28	3.61	0.57	-13.37	8.33	-38.4	38.0
Week 37	n/a		59	88.1	53	89.8	40.83	22.18	3.84	18.78	-1.44	9.12	3.85	-8.64	12.16	-34.7	56.1
Week 49	n/a		52	77.6	48	92.3	43.97	19.65	8.00	17.28	2.93	13.08	6.00	-3.73	18.37	-24.3	49.2
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	34.15	17.48	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	39.32	18.80	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	30.42	19.92	-2.03	9.82	-7.70	3.64	1.56	-10.67	5.67	-24.1	9.3
	Moderate		46	68.7	38	82.6	35.53	19.15	-3.20	10.89	-6.83	0.43	-3.88	-9.07	5.55	-29.6	21.9
Week 25	Mild		19	28.4	14	73.7	39.87	20.47	6.28	17.87	-4.52	17.07	6.48	0.05	14.42	-33.9	31.2
	Moderate		46	68.7	38	82.6	35.01	22.71	-4.01	16.64	-9.56	1.54	-1.66	-15.22	4.70	-38.4	38.0
Week 37	Mild		15	22.4	13	86.7	44.84	19.58	11.08	13.13	2.73	19.42	9.71	2.99	19.55	-10.1	37.9
	Moderate		44	65.7	40	90.9	39.53	23.04	1.62	19.82	-4.81	8.04	2.80	-10.25	10.64	-34.7	56.1
Week 49	Mild		13	19.4	12	92.3	43.53	23.40	11.78	17.12	0.90	22.66	15.62	-2.60	22.23	-19.7	39.6
	Moderate		39	58.2	36	92.3	44.12	18.62	6.71	17.38	0.74	12.68	3.34	-3.73	17.32	-24.3	49.2

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_LPAM\_SG.xls

16MAR2022 12:48

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Locomotion (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_LPAM\_SG.pdf  
16MAR2022 15:47

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Locomotion (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_LPAM\_SG.pdf  
16MAR2022 15:47

**POPULATION: Treated Patients Aged  $\geq$  5 years**  
**ENDPOINT: Physical Activity: Mean of Daily Locomotion (min)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_LPAM\_SG.pdf  
16MAR2022 15:47



POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Moderate Physical Activity (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean


		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	112.81	42.78	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	116.26	41.40	0.79	30.68	-7.84	9.42	0.04	-19.71	17.77	-64.3	72.7
Week 25	n/a		65	97.0	52	80.0	121.74	48.03	5.86	42.30	-6.16	17.88	10.94	-15.06	34.26	-117.7	87.5
Week 37	n/a		59	88.1	53	89.8	126.34	46.26	12.61	44.10	0.21	25.02	4.55	-12.77	38.34	-103.0	118.3
Week 49	n/a		52	77.6	48	92.3	125.39	42.11	13.53	32.19	4.08	22.98	13.45	-5.16	36.04	-58.3	84.5
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	93.57	30.30	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	121.51	45.01	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	105.69	31.22	9.55	31.26	-8.50	27.60	3.03	-6.21	19.74	-51.4	72.7
	Moderate		46	68.7	38	82.6	120.43	44.46	-2.52	30.23	-12.60	7.55	-1.20	-20.21	11.52	-64.3	59.5
Week 25	Mild		19	28.4	14	73.7	118.42	45.37	24.53	29.53	6.69	42.38	23.95	7.92	46.44	-22.7	76.5
	Moderate		46	68.7	38	82.6	122.97	49.50	-0.70	44.44	-15.52	14.11	8.62	-16.98	23.02	-117.7	87.5
Week 37	Mild		15	22.4	13	86.7	118.55	29.90	26.04	33.00	5.07	47.00	22.15	8.69	34.34	-15.9	96.5
	Moderate		44	65.7	40	90.9	128.87	50.52	8.48	46.58	-6.61	23.58	0.22	-16.87	38.34	-103.0	118.3
Week 49	Mild		13	19.4	12	92.3	113.37	35.22	24.07	33.81	2.59	45.56	22.20	7.14	44.51	-45.5	84.5
	Moderate		39	58.2	36	92.3	129.40	43.89	9.91	31.30	-0.84	20.66	9.54	-9.36	36.04	-58.3	61.5

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_MPAM\_SG.xls  
 16MAR2022 12:51

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Moderate Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_MPAM\_SG.pdf  
16MAR2022 15:48

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Moderate Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_MPAM\_SG.pdf  
16MAR2022 15:48

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Moderate Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_MPAM\_SG.pdf  
16MAR2022 15:48

POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Normalized Daily Steps Count (cts/hrs)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean


Emicizumab (N=67)																	
		Patients				Statistics for Score		Statistics for Change from Baseline									
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	458.61	175.70	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	435.10	151.80	-9.99	117.61	-43.06	23.09	7.68	-89.79	63.26	-397.3	215.0
Week 25	n/a		65	97.0	52	80.0	450.86	173.11	1.69	200.03	-55.15	58.54	10.52	-59.61	120.78	-549.9	417.2
Week 37	n/a		59	88.1	53	89.8	481.09	162.41	38.13	217.68	-23.09	99.36	19.51	-45.27	129.83	-608.2	639.5
Week 49	n/a		52	77.6	48	92.3	515.92	139.16	66.45	174.02	15.36	117.55	63.64	-31.30	197.19	-393.1	501.5
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	422.80	183.65	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	474.81	171.77	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	406.11	154.60	-10.29	105.46	-71.18	50.59	4.57	-89.01	57.14	-179.1	153.9
	Moderate		46	68.7	38	82.6	446.54	151.22	-9.87	123.27	-50.97	31.23	17.69	-89.79	89.42	-397.3	215.0
Week 25	Mild		19	28.4	14	73.7	477.56	203.17	70.55	168.07	-31.01	172.11	12.54	-21.48	136.83	-257.6	384.2
	Moderate		46	68.7	38	82.6	441.02	162.59	-22.50	206.72	-91.42	46.43	8.51	-69.96	96.78	-549.9	417.2
Week 37	Mild		15	22.4	13	86.7	479.30	188.55	70.69	209.98	-62.72	204.11	36.00	-23.60	226.65	-280.7	519.3
	Moderate		44	65.7	40	90.9	481.67	155.66	28.11	221.70	-43.75	99.98	8.85	-57.95	99.02	-608.2	639.5
Week 49	Mild		13	19.4	12	92.3	462.30	163.82	56.62	186.18	-61.68	174.91	44.74	-19.99	204.40	-300.8	345.2
	Moderate		39	58.2	36	92.3	533.79	127.50	69.83	172.37	10.62	129.04	63.64	-31.30	172.90	-393.1	501.5

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_NDSM\_SG.xls  
 16MAR2022 12:52

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Normalized Daily Steps Count (cts/hrs)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NDSM\_SG.pdf  
16MAR2022 15:48

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Normalized Daily Steps Count (cts/hrs)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NDSM\_SG.pdf  
16MAR2022 15:48

**POPULATION:** Treated Patients Aged  $\geq$  5 years  
**ENDPOINT:** Physical Activity: Mean of Normalized Daily Steps Count (cts/hrs)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NDSM\_SG.pdf  
16MAR2022 15:48



POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Non-Locomotion (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean


		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	797.66	78.78	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	814.35	74.90	21.71	87.77	-2.98	46.39	7.58	-19.80	55.05	-120.6	440.7
Week 25	n/a		65	97.0	52	80.0	796.45	86.12	5.41	80.73	-17.53	28.36	-2.05	-44.67	45.37	-162.5	288.5
Week 37	n/a		59	88.1	53	89.8	812.49	87.30	16.68	102.78	-12.23	45.59	8.43	-44.43	53.41	-149.3	413.1
Week 49	n/a		52	77.6	48	92.3	824.48	67.98	27.27	93.52	-0.19	54.73	15.25	-19.35	54.52	-142.9	357.5
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	767.02	81.90	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	811.53	74.21	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	812.68	83.37	55.77	127.18	-17.67	129.20	33.32	-17.60	64.09	-84.2	440.7
	Moderate		46	68.7	38	82.6	815.01	72.48	8.82	65.10	-12.88	30.53	7.43	-21.91	38.91	-120.6	212.9
Week 25	Mild		19	28.4	14	73.7	781.00	59.70	22.01	84.22	-28.88	72.91	14.47	-20.77	44.23	-94.3	232.9
	Moderate		46	68.7	38	82.6	802.14	94.06	-0.42	79.83	-27.04	26.20	-9.63	-58.12	45.37	-162.5	288.5
Week 37	Mild		15	22.4	13	86.7	802.33	82.19	43.09	127.78	-38.10	124.28	25.81	-26.43	66.61	-78.9	409.9
	Moderate		44	65.7	40	90.9	815.79	89.65	8.56	94.26	-22.00	39.11	1.16	-44.43	52.31	-149.3	413.1
Week 49	Mild		13	19.4	12	92.3	818.40	71.60	59.71	119.71	-16.34	135.77	44.59	-16.68	94.25	-116.5	357.5
	Moderate		39	58.2	36	92.3	826.51	67.66	16.15	81.84	-11.97	44.26	8.84	-19.35	39.11	-142.9	337.7

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_NLPAM\_SG.xls  
 16MAR2022 12:54

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Non-Locomotion (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NLPAM\_SG.pdf  
16MAR2022 15:49

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Non-Locomotion (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NLPAM\_SG.pdf  
16MAR2022 15:49

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Non-Locomotion (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NLPAM\_SG.pdf  
16MAR2022 15:49


POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Non-Sedentary Behaviour (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

Emicizumab (N=67)																	
		Patients				Statistics for Score		Statistics for Change from Baseline									
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	426.45	101.99	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	424.79	98.90	-0.48	67.57	-19.49	18.52	-20.07	-35.41	32.09	-141.4	226.8
Week 25	n/a		65	97.0	52	80.0	429.83	112.16	2.53	82.25	-20.85	25.90	5.29	-37.60	45.36	-197.9	189.6
Week 37	n/a		59	88.1	53	89.8	446.44	103.13	21.02	93.53	-5.28	47.33	10.28	-30.66	77.90	-214.6	230.0
Week 49	n/a		52	77.6	48	92.3	451.05	92.30	24.71	68.00	4.74	44.67	21.09	-30.75	75.95	-128.0	189.7
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	386.65	84.19	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	444.46	105.09	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	406.54	93.63	21.55	79.79	-24.51	67.62	-13.43	-32.94	39.18	-61.3	226.8
	Moderate		46	68.7	38	82.6	431.99	101.21	-8.82	61.50	-29.32	11.69	-21.13	-35.41	23.62	-141.4	156.2
Week 25	Mild		19	28.4	14	73.7	429.45	80.32	45.09	74.73	-0.07	90.25	20.31	-7.01	111.70	-47.1	189.6
	Moderate		46	68.7	38	82.6	429.96	122.77	-12.42	80.39	-39.23	14.38	-2.73	-63.71	32.83	-197.9	181.2
Week 37	Mild		15	22.4	13	86.7	423.56	62.81	44.49	103.48	-21.26	110.23	32.07	-30.08	105.72	-124.8	230.0
	Moderate		44	65.7	40	90.9	453.88	112.85	13.80	90.46	-15.52	43.13	3.35	-30.66	68.48	-214.6	200.2
Week 49	Mild		13	19.4	12	92.3	420.62	76.65	38.96	84.52	-14.74	92.67	38.58	-13.08	87.31	-128.0	189.7
	Moderate		39	58.2	36	92.3	461.20	95.76	19.82	62.03	-1.49	41.13	14.70	-30.75	61.74	-94.0	162.8

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Non-Sedentary Behaviour (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NSPAM\_SG.pdf  
16MAR2022 15:49

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Non-Sedentary Behaviour (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NSPAM\_SG.pdf  
16MAR2022 15:49

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Non-Sedentary Behaviour (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_NSPAM\_SG.pdf  
16MAR2022 15:49



POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Peak Activity Duration (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	129.91	56.32	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	132.27	52.24	-2.07	34.42	-11.75	7.61	-3.07	-21.37	17.45	-74.4	68.1
Week 25	n/a		65	97.0	52	80.0	138.12	57.47	3.86	52.89	-11.18	18.89	11.92	-13.35	33.28	-178.0	95.6
Week 37	n/a		59	88.1	53	89.8	145.96	58.84	14.14	54.62	-1.22	29.51	6.52	-11.39	44.00	-128.7	158.8
Week 49	n/a		52	77.6	48	92.3	145.24	53.42	17.00	40.43	5.13	28.87	16.83	-4.02	36.53	-69.2	91.4
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	104.53	38.65	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	141.39	59.60	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	118.02	40.88	7.48	34.26	-12.30	27.26	0.05	-7.47	17.45	-54.7	68.1
	Moderate		46	68.7	38	82.6	137.89	55.57	-5.68	34.24	-17.10	5.74	-4.80	-22.75	16.63	-74.4	56.3
Week 25	Mild		19	28.4	14	73.7	133.56	56.67	28.80	37.33	6.24	51.36	24.72	7.66	49.04	-31.7	93.2
	Moderate		46	68.7	38	82.6	139.81	58.42	-4.91	55.14	-23.29	13.48	8.25	-23.48	24.54	-178.0	95.6
Week 37	Mild		15	22.4	13	86.7	137.32	40.32	32.38	41.01	6.32	58.43	25.37	9.34	46.88	-17.4	129.6
	Moderate		44	65.7	40	90.9	148.76	63.90	8.53	57.46	-10.09	27.16	-1.44	-14.47	44.00	-128.7	158.8
Week 49	Mild		13	19.4	12	92.3	126.20	39.97	27.96	37.05	4.42	51.50	26.78	8.26	52.78	-46.7	84.4
	Moderate		39	58.2	36	92.3	151.59	56.25	13.24	41.36	-0.97	27.44	10.12	-9.83	35.63	-69.2	91.4

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_PADM\_SG.xls

16MAR2022 12:55

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Peak Activity Duration (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_PADM\_SG.pdf  
16MAR2022 15:50

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Peak Activity Duration (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_PADM\_SG.pdf  
16MAR2022 15:50

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Peak Activity Duration (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_PADM\_SG.pdf  
16MAR2022 15:50

POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Sedentary Behaviour (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	408.92	67.47	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	423.65	63.23	19.31	51.97	4.69	33.93	13.76	-20.04	52.51	-67.5	189.7
Week 25	n/a		65	97.0	52	80.0	402.95	74.72	1.55	68.60	-17.95	21.05	-1.63	-47.17	43.92	-156.2	185.5
Week 37	n/a		59	88.1	53	89.8	406.88	69.29	-0.50	84.48	-24.26	23.26	-6.56	-62.19	46.23	-157.6	223.6
Week 49	n/a		52	77.6	48	92.3	417.40	66.97	10.57	68.21	-9.46	30.59	0.01	-32.69	47.53	-121.5	178.3
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	414.52	41.61	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	406.39	76.69	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	436.56	53.74	32.19	61.74	-3.46	67.83	15.95	-18.42	61.90	-29.3	189.7
	Moderate		46	68.7	38	82.6	418.55	66.57	14.44	47.82	-1.51	30.38	13.76	-20.07	48.88	-67.5	119.0
Week 25	Mild		19	28.4	14	73.7	391.42	51.43	-16.80	53.39	-49.06	15.47	-24.20	-47.17	0.63	-89.4	83.1
	Moderate		46	68.7	38	82.6	407.19	81.83	8.00	72.74	-16.26	32.25	10.86	-45.12	45.24	-156.2	185.5
Week 37	Mild		15	22.4	13	86.7	423.61	61.05	9.68	91.83	-48.67	68.03	-11.76	-66.53	63.64	-90.1	198.0
	Moderate		44	65.7	40	90.9	401.45	71.63	-3.63	83.11	-30.57	23.31	-6.37	-55.22	46.23	-157.6	223.6
Week 49	Mild		13	19.4	12	92.3	441.31	38.65	32.53	77.39	-16.64	81.71	14.31	-23.32	90.12	-78.8	177.7
	Moderate		39	58.2	36	92.3	409.43	72.74	3.04	64.25	-19.03	25.10	-0.93	-33.36	45.59	-121.5	178.3

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_SPAM\_SG.xls

16MAR2022 12:57

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Sedentary Behaviour (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_SPAM\_SG.pdf  
16MAR2022 15:50

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Sedentary Behaviour (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_SPAM\_SG.pdf  
16MAR2022 15:50

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Sedentary Behaviour (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_SPAM\_SG.pdf  
16MAR2022 15:50



POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Total Activity Counts (cts/min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean


		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	1547.50	507.62	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	1567.55	489.83	4.40	314.59	-84.08	92.88	-13.45	-150.42	175.86	-604.6	1081.4
Week 25	n/a		65	97.0	52	80.0	1581.55	538.67	23.39	413.31	-94.07	140.85	39.11	-100.20	287.80	-1283.3	720.6
Week 37	n/a		59	88.1	53	89.8	1635.56	498.66	95.19	432.61	-26.48	216.87	48.65	-82.15	357.96	-1334.0	1162.7
Week 49	n/a		52	77.6	48	92.3	1630.65	480.91	93.32	314.02	1.12	185.53	93.81	-173.39	275.95	-625.5	759.3
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	1350.58	367.01	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	1636.58	540.24	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	1471.68	445.26	103.87	373.78	-111.95	319.68	6.34	-95.83	179.20	-347.5	1081.4
	Moderate		46	68.7	38	82.6	1605.40	506.94	-33.24	285.83	-128.54	62.06	-35.14	-150.42	160.42	-604.6	513.5
Week 25	Mild		19	28.4	14	73.7	1545.65	461.69	245.66	315.67	54.90	436.42	107.74	27.45	616.03	-180.6	720.6
	Moderate		46	68.7	38	82.6	1594.78	569.55	-54.71	418.56	-194.26	84.85	-1.93	-204.28	198.60	-1283.3	579.5
Week 37	Mild		15	22.4	13	86.7	1504.47	271.29	226.87	374.74	-11.23	464.96	112.71	2.18	480.15	-451.6	851.0
	Moderate		44	65.7	40	90.9	1678.17	548.92	54.68	445.46	-89.72	199.08	19.19	-86.07	282.23	-1334.0	1162.7
Week 49	Mild		13	19.4	12	92.3	1421.03	235.13	157.46	323.04	-47.79	362.71	178.65	-86.25	363.97	-387.2	703.6
	Moderate		39	58.2	36	92.3	1700.53	522.60	71.33	312.58	-36.04	178.71	67.92	-173.39	249.16	-625.5	759.3

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_TACTM\_SG.xls  
 16MAR2022 12:58

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Total Activity Counts (cts/min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_TACTM\_SG.pdf  
16MAR2022 15:51

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Total Activity Counts (cts/min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_TACTM\_SG.pdf  
16MAR2022 15:51

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Total Activity Counts (cts/min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_TACTM\_SG.pdf  
16MAR2022 15:51

POPULATION: Treated Patients Aged >= 5 years  
 ENDPOINT: Physical Activity: Mean of Daily Vigorous Physical Activity (min)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=67)															
		Patients				Statistics for Score				Statistics for Change from Baseline							
Name	Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD	95% lower CL for mean	95% upper CL for mean	median	1st quartile	3rd quartile	min	max
All																	
Baseline	n/a		67	100.0	61	91.0	17.11	16.36	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	n/a		66	98.5	53	80.3	16.01	13.64	-2.86	8.21	-5.17	-0.55	-2.71	-7.36	0.55	-24.1	16.9
Week 25	n/a		65	97.0	52	80.0	16.38	13.31	-2.00	13.96	-5.97	1.97	0.24	-3.44	4.93	-60.2	28.5
Week 37	n/a		59	88.1	53	89.8	19.62	16.77	1.53	13.57	-2.29	5.35	0.56	-4.23	4.90	-42.4	40.5
Week 49	n/a		52	77.6	48	92.3	19.85	15.20	3.47	12.39	-0.17	7.11	0.93	-1.23	9.54	-29.1	48.3
Hemophilia severity																	
Baseline	Mild		21	31.3	19	90.5	10.97	12.10	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Moderate		46	68.7	42	91.3	19.88	17.38	NE	NE	NE	NE	NE	NE	NE	NE	NE
Week 13	Mild		20	29.9	15	75.0	12.33	12.53	-2.08	6.56	-5.86	1.71	-2.71	-4.78	0.12	-10.5	16.9
	Moderate		46	68.7	38	82.6	17.46	13.94	-3.16	8.82	-6.10	-0.22	-2.71	-7.36	0.55	-24.1	16.1
Week 25	Mild		19	28.4	14	73.7	15.14	14.42	4.27	8.66	-0.97	9.50	0.77	-0.26	9.09	-9.0	23.6
	Moderate		46	68.7	38	82.6	16.84	13.05	-4.20	14.87	-9.16	0.75	-0.07	-11.64	3.88	-60.2	28.5
Week 37	Mild		15	22.4	13	86.7	18.78	12.84	6.34	9.95	0.01	12.66	3.57	-0.03	9.80	-2.4	33.1
	Moderate		44	65.7	40	90.9	19.89	18.00	0.05	14.29	-4.58	4.68	0.08	-5.48	4.46	-42.4	40.5
Week 49	Mild		13	19.4	12	92.3	12.83	10.27	3.89	9.13	-1.92	9.69	0.85	-0.46	13.93	-14.2	16.9
	Moderate		39	58.2	36	92.3	22.19	15.96	3.32	13.45	-1.30	7.94	0.94	-1.70	7.25	-29.1	48.3

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean2\_DEC21\_TRTGE5\_VPAM\_SG.xls

16MAR2022 12:58

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Vigorous Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=67)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_VPAM\_SG.pdf  
16MAR2022 15:52

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Vigorous Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=21)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_VPAM\_SG.pdf  
16MAR2022 15:52

**POPULATION:** Treated Patients Aged  $\geq 5$  years  
**ENDPOINT:** Physical Activity: Mean of Daily Vigorous Physical Activity (min)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=46)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE5\_VPAM\_SG.pdf  
16MAR2022 15:52



POPULATION: Treated Patients Aged < 8 years (Caregivers)  
 ENDPOINT: CATCH Caregiver: Like To Have Child With Hemophilia  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=10)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	10	100.0	10	100.0	53.54	17.84	NE	NE
Week 1 Day 1	n/a	10	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	10	100.0	9	90.0	46.30	23.08	-6.02	11.48
Week 25 Day 169	n/a	10	100.0	9	90.0	46.99	16.86	-9.95	10.09
Week 37 Day 253	n/a	10	100.0	10	100.0	43.54	15.17	-10.00	15.40
Week 49 Day 337	n/a	10	100.0	9	90.0	43.52	19.44	-10.65	13.95
Week 61 Day 421	n/a	8	80.0	2	25.0	38.54	19.15	-23.96	16.20
Week 73 Day 505	n/a	3	30.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	1	10.0	1	100.0	47.92	NE	NE	NE
	Moderate	9	90.0	9	100.0	54.17	18.81	NE	NE
Week 1 Day 1	Mild	1	10.0	0	0.0	NE	NE	NE	NE
	Moderate	9	90.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	1	10.0	1	100.0	52.08	NE	4.17	NE
	Moderate	9	90.0	8	88.9	45.57	24.56	-7.29	11.57
Week 25 Day 169	Mild	1	10.0	1	100.0	56.25	NE	8.33	NE
	Moderate	9	90.0	8	88.9	45.83	17.64	-12.24	7.91
Week 37 Day 253	Mild	1	10.0	1	100.0	52.08	NE	4.17	NE
	Moderate	9	90.0	9	100.0	42.59	15.77	-11.57	15.45
Week 49 Day 337	Mild	1	10.0	0	0.0	NE	NE	NE	NE
	Moderate	9	90.0	9	100.0	43.52	19.44	-10.65	13.95
Week 61 Day 421	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	8	80.0	2	25.0	38.54	19.15	-23.96	16.20
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	3	30.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTLT8\_CHHEM\_SG.xls

15MAR2022 16:34

**POPULATION: Treated Patients Aged < 8 years (Caregivers)**  
**ENDPOINT: CATCH Caregiver: Like To Have Child With Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=10)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTLT8\_CHHEM\_SG.pdf  
16MAR2022 15:18

**POPULATION: Treated Patients Aged < 8 years (Caregivers)**  
**ENDPOINT: CATCH Caregiver: Like To Have Child With Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=1)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTLT8\_CHEM\_SG.pdf  
16MAR2022 15:18

**POPULATION: Treated Patients Aged < 8 years (Caregivers)**  
**ENDPOINT: CATCH Caregiver: Like To Have Child With Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=9)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTLT8\_CHHEM\_SG.pdf  
16MAR2022 15:18

POPULATION: Treated Patients Aged < 8 years (Caregivers)  
 ENDPPOINT: CATCH Caregiver: Treatment/Caring For Child With Hemophilia  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=10)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	10	100.0	10	100.0	43.93	21.50	NE	NE
Week 1 Day 1	n/a	10	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	10	100.0	9	90.0	28.17	16.02	-13.49	16.34
Week 25 Day 169	n/a	10	100.0	9	90.0	27.78	20.26	-18.65	16.44
Week 37 Day 253	n/a	10	100.0	10	100.0	23.93	16.59	-20.00	14.79
Week 49 Day 337	n/a	10	100.0	9	90.0	26.98	23.36	-15.48	15.46
Week 61 Day 421	n/a	8	80.0	2	25.0	7.14	10.10	-17.86	15.15
Week 73 Day 505	n/a	3	30.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	1	10.0	1	100.0	57.14	NE	NE	NE
	Moderate	9	90.0	9	100.0	42.46	22.26	NE	NE
Week 1 Day 1	Mild	1	10.0	0	0.0	NE	NE	NE	NE
	Moderate	9	90.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	1	10.0	1	100.0	17.86	NE	-39.29	NE
	Moderate	9	90.0	8	88.9	29.46	16.61	-10.27	14.09
Week 25 Day 169	Mild	1	10.0	1	100.0	3.57	NE	-53.57	NE
	Moderate	9	90.0	8	88.9	30.80	19.37	-14.29	10.63
Week 37 Day 253	Mild	1	10.0	1	100.0	25.00	NE	-32.14	NE
	Moderate	9	90.0	9	100.0	23.81	17.59	-18.65	15.02
Week 49 Day 337	Mild	1	10.0	0	0.0	NE	NE	NE	NE
	Moderate	9	90.0	9	100.0	26.98	23.36	-15.48	15.46
Week 61 Day 421	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	8	80.0	2	25.0	7.14	10.10	-17.86	15.15
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	3	30.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTLT8\_TCHHEM\_SG.xls

15MAR2022 16:35

**POPULATION: Treated Patients Aged < 8 years (Caregivers)**  
**ENDPOINT: CATCH Caregiver: Treatment/Caring For Child With Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=10)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTLT8\_TCHHEM\_SG.pdf  
16MAR2022 15:19

**POPULATION: Treated Patients Aged < 8 years (Caregivers)**  
**ENDPOINT: CATCH Caregiver: Treatment/Caring For Child With Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=1)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTLT8\_TCHHEM\_SG.pdf  
16MAR2022 15:19

**POPULATION: Treated Patients Aged < 8 years (Caregivers)**  
**ENDPOINT: CATCH Caregiver: Treatment/Caring For Child With Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=9)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTLT8\_TCHHEM\_SG.pdf  
16MAR2022 15:19



POPULATION: Treated Patients Aged 8-17 years  
 ENDPPOINT: CATCH Pediatric: Careful About Hemophilia  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	47.98	25.81	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	20	100.0	45.60	31.47	-2.38	40.16
Week 25 Day 169	n/a	20	100.0	20	100.0	40.55	24.43	-7.43	30.68
Week 37 Day 253	n/a	20	100.0	19	95.0	40.84	20.17	-6.18	26.73
Week 49 Day 337	n/a	20	100.0	19	95.0	38.32	28.80	-7.82	28.88
Week 61 Day 421	n/a	14	70.0	10	71.4	39.70	30.54	-8.30	19.56
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	49.63	30.31	NE	NE
	Moderate	16	80.0	16	100.0	47.56	25.68	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	45.50	24.89	-4.13	47.80
	Moderate	16	80.0	16	100.0	45.63	33.62	-1.94	39.81
Week 25 Day 169	Mild	4	20.0	4	100.0	37.25	20.99	-12.38	36.89
	Moderate	16	80.0	16	100.0	41.38	25.78	-6.19	30.20
Week 37 Day 253	Mild	4	20.0	3	75.0	27.50	9.53	-16.67	28.87
	Moderate	16	80.0	16	100.0	43.34	20.83	-4.22	26.84
Week 49 Day 337	Mild	4	20.0	3	75.0	33.00	33.00	-5.50	25.20
	Moderate	16	80.0	16	100.0	39.31	29.04	-8.25	30.25
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	10	76.9	39.70	30.54	-8.30	19.56
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_CARHEM\_SG.xls

15MAR2022 16:26

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Careful About Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_CARHEM\_SG.pdf  
16MAR2022 15:08

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Careful About Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_CARHEM\_SG.pdf  
16MAR2022 15:08

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Careful About Hemophilia**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_CARHEM\_SG.pdf  
16MAR2022 15:08

POPULATION: Treated Patients Aged 8-17 years  
 ENDPPOINT: CATCH Pediatric: Daily Activities (Bleed)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	7.50	8.89	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	20	100.0	3.39	4.84	-4.11	7.71
Week 25 Day 169	n/a	20	100.0	20	100.0	3.57	5.68	-3.93	8.10
Week 37 Day 253	n/a	20	100.0	19	95.0	4.14	10.05	-3.76	11.99
Week 49 Day 337	n/a	20	100.0	19	95.0	4.70	10.03	-3.01	11.92
Week 61 Day 421	n/a	14	70.0	10	71.4	7.50	14.33	-2.86	16.73
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	3.57	5.05	NE	NE
	Moderate	16	80.0	16	100.0	8.48	9.48	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	0.89	1.79	-2.68	5.36
	Moderate	16	80.0	16	100.0	4.02	5.20	-4.46	8.30
Week 25 Day 169	Mild	4	20.0	4	100.0	0.89	1.79	-2.68	5.36
	Moderate	16	80.0	16	100.0	4.24	6.15	-4.24	8.77
Week 37 Day 253	Mild	4	20.0	3	75.0	0.00	0.00	-4.76	5.46
	Moderate	16	80.0	16	100.0	4.91	10.82	-3.57	12.98
Week 49 Day 337	Mild	4	20.0	3	75.0	0.00	0.00	-3.57	6.19
	Moderate	16	80.0	16	100.0	5.58	10.75	-2.90	12.86
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	10	76.9	7.50	14.33	-2.86	16.73
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_DABLD\_SG.xls

15MAR2022 16:26

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Daily Activities (Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_DABLD\_SG.pdf  
16MAR2022 15:09

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Daily Activities (Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_DABLD\_SG.pdf  
16MAR2022 15:09

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Daily Activities (Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_DABLD\_SG.pdf  
16MAR2022 15:09



POPULATION: Treated Patients Aged 8-17 years  
 ENDPOINT: CATCH Pediatric: Daily Activities (Hard)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	6.01	12.94	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	20	100.0	3.54	5.33	-2.48	10.19
Week 25 Day 169	n/a	20	100.0	20	100.0	4.83	8.53	-1.18	9.03
Week 37 Day 253	n/a	20	100.0	19	95.0	4.22	9.13	-2.11	16.58
Week 49 Day 337	n/a	20	100.0	19	95.0	6.58	11.59	0.37	13.71
Week 61 Day 421	n/a	14	70.0	10	71.4	4.02	11.10	-0.46	12.65
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	4.71	7.94	NE	NE
	Moderate	16	80.0	16	100.0	6.33	14.11	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	1.77	2.26	-2.95	5.89
	Moderate	16	80.0	16	100.0	3.98	5.82	-2.36	11.16
Week 25 Day 169	Mild	4	20.0	4	100.0	3.54	5.61	-1.18	2.36
	Moderate	16	80.0	16	100.0	5.16	9.24	-1.18	10.11
Week 37 Day 253	Mild	4	20.0	3	75.0	0.00	0.00	-6.29	8.92
	Moderate	16	80.0	16	100.0	5.01	9.78	-1.32	17.75
Week 49 Day 337	Mild	4	20.0	3	75.0	0.00	0.00	-5.50	9.53
	Moderate	16	80.0	16	100.0	7.81	12.28	1.47	14.32
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	10	76.9	4.02	11.10	-0.46	12.65
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_DAHARD\_SG.xls

15MAR2022 16:27

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Daily Activities (Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_DAHARD\_SG.pdf  
16MAR2022 15:10

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Daily Activities (Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_DAHARD\_SG.pdf  
16MAR2022 15:10

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Daily Activities (Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_DAHARD\_SG.pdf  
16MAR2022 15:10

POPULATION: Treated Patients Aged 8-17 years  
 ENDPOINT: CATCH Pediatric: Feel About Hemophilia Treatments  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	38.91	27.98	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	20	100.0	52.21	23.02	13.30	26.72
Week 25 Day 169	n/a	20	100.0	20	100.0	57.20	23.75	18.29	26.56
Week 37 Day 253	n/a	20	100.0	19	95.0	55.47	19.81	16.25	30.54
Week 49 Day 337	n/a	20	100.0	19	95.0	49.39	25.26	10.46	30.16
Week 61 Day 421	n/a	14	70.0	10	71.4	53.12	34.50	16.15	31.18
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	37.21	22.76	NE	NE
	Moderate	16	80.0	16	100.0	39.33	29.79	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	52.42	19.54	15.21	30.64
	Moderate	16	80.0	16	100.0	52.16	24.39	12.82	26.75
Week 25 Day 169	Mild	4	20.0	4	100.0	45.50	22.37	8.29	35.81
	Moderate	16	80.0	16	100.0	60.13	23.85	20.79	24.57
Week 37 Day 253	Mild	4	20.0	3	75.0	47.72	11.42	9.11	21.04
	Moderate	16	80.0	16	100.0	56.93	20.95	17.59	32.38
Week 49 Day 337	Mild	4	20.0	3	75.0	51.39	20.86	14.61	30.47
	Moderate	16	80.0	16	100.0	49.02	26.58	9.69	31.05
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	10	76.9	53.12	34.50	16.15	31.18
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_FHEMTR\_SG.xls

15MAR2022 16:28

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Feel About Hemophilia Treatments**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_FHEMTR\_SG.pdf  
16MAR2022 15:13

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Feel About Hemophilia Treatments**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_FHEMTR\_SG.pdf  
16MAR2022 15:13

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Feel About Hemophilia Treatments**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_FHEMTR\_SG.pdf  
16MAR2022 15:13



POPULATION: Treated Patients Aged 8-17 years  
 ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Bleed)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	41.57	29.94	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	19	95.0	31.01	18.80	-11.17	23.16
Week 25 Day 169	n/a	20	100.0	17	85.0	27.05	20.61	-7.47	24.89
Week 37 Day 253	n/a	20	100.0	18	90.0	28.68	24.23	-14.15	32.78
Week 49 Day 337	n/a	20	100.0	19	95.0	32.18	25.33	-10.00	28.75
Week 61 Day 421	n/a	14	70.0	9	64.3	38.45	23.95	-26.26	33.30
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	14.17	12.58	NE	NE
	Moderate	16	80.0	16	100.0	48.42	29.21	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	12.50	15.00	-1.67	5.77
	Moderate	16	80.0	15	93.8	35.94	16.80	-13.70	25.49
Week 25 Day 169	Mild	4	20.0	4	100.0	20.83	25.00	6.67	18.66
	Moderate	16	80.0	13	81.3	28.97	19.83	-11.83	25.53
Week 37 Day 253	Mild	4	20.0	3	75.0	11.67	12.58	-1.67	2.89
	Moderate	16	80.0	15	93.8	32.08	24.82	-16.65	35.55
Week 49 Day 337	Mild	4	20.0	3	75.0	11.11	19.25	2.22	13.47
	Moderate	16	80.0	16	100.0	36.13	24.80	-12.29	30.53
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	9	69.2	38.45	23.95	-26.26	33.30
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_RADBLD\_SG.xls

15MAR2022 16:29

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_RADBLD\_SG.pdf  
16MAR2022 15:13

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_RADBLD\_SG.pdf  
16MAR2022 15:13

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_RADBLD\_SG.pdf  
16MAR2022 15:13

POPULATION: Treated Patients Aged 8-17 years  
 ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Hard)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	14.51	14.70	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	19	95.0	19.03	18.22	3.75	16.90
Week 25 Day 169	n/a	20	100.0	17	85.0	14.74	14.68	3.07	15.32
Week 37 Day 253	n/a	20	100.0	18	90.0	14.37	19.14	-0.38	25.40
Week 49 Day 337	n/a	20	100.0	19	95.0	13.59	17.74	-0.99	21.42
Week 61 Day 421	n/a	14	70.0	9	64.3	12.38	10.84	-10.10	11.54
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	11.55	15.60	NE	NE
	Moderate	16	80.0	16	100.0	15.25	14.90	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	11.55	15.60	0.00	0.00
	Moderate	16	80.0	15	93.8	21.02	18.83	4.75	19.02
Week 25 Day 169	Mild	4	20.0	4	100.0	12.38	15.80	0.83	1.65
	Moderate	16	80.0	13	81.3	15.47	14.91	3.75	17.60
Week 37 Day 253	Mild	4	20.0	3	75.0	4.95	4.37	-10.45	20.36
	Moderate	16	80.0	15	93.8	16.25	20.48	1.63	26.42
Week 49 Day 337	Mild	4	20.0	3	75.0	0.00	0.00	-11.00	19.05
	Moderate	16	80.0	16	100.0	16.14	18.27	0.89	21.88
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	9	69.2	12.38	10.84	-10.10	11.54
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_RADHRD\_SG.xls

15MAR2022 16:30

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_RADHRD\_SG.pdf  
16MAR2022 15:14

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_RADHRD\_SG.pdf  
16MAR2022 15:14

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Recreational Activities (Do, Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_RADHRD\_SG.pdf  
16MAR2022 15:14



POPULATION: Treated Patients Aged 8-17 years  
 ENDPOINT: CATCH Pediatric: Social Activities (Bleed)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	16.79	15.76	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	20	100.0	11.43	8.79	-5.36	12.45
Week 25 Day 169	n/a	20	100.0	20	100.0	12.14	7.36	-4.64	14.15
Week 37 Day 253	n/a	20	100.0	19	95.0	13.16	11.23	-4.51	16.87
Week 49 Day 337	n/a	20	100.0	19	95.0	12.41	11.13	-4.51	16.70
Week 61 Day 421	n/a	14	70.0	10	71.4	15.71	9.40	-10.00	19.11
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	3.57	7.14	NE	NE
	Moderate	16	80.0	16	100.0	20.09	15.70	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	3.57	7.14	0.00	0.00
	Moderate	16	80.0	16	100.0	13.39	8.20	-6.70	13.67
Week 25 Day 169	Mild	4	20.0	4	100.0	12.50	8.99	8.93	10.71
	Moderate	16	80.0	16	100.0	12.05	7.25	-8.04	13.01
Week 37 Day 253	Mild	4	20.0	3	75.0	4.76	8.25	0.00	0.00
	Moderate	16	80.0	16	100.0	14.73	11.21	-5.36	18.35
Week 49 Day 337	Mild	4	20.0	3	75.0	4.76	8.25	4.76	8.25
	Moderate	16	80.0	16	100.0	13.84	11.21	-6.25	17.47
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	10	76.9	15.71	9.40	-10.00	19.11
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_SABLD\_SG.xls

15MAR2022 16:32

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Social Activities (Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SABLD\_SG.pdf  
16MAR2022 15:17

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Social Activities (Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SABLD\_SG.pdf  
16MAR2022 15:17

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Social Activities (Bleed)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SABLD\_SG.pdf  
16MAR2022 15:17

POPULATION: Treated Patients Aged 8-17 years  
 ENDPPOINT: CATCH Pediatric: Social Activities (Hard)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	20	100.0	7.07	8.45	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	20	100.0	6.37	6.38	-0.70	7.70
Week 25 Day 169	n/a	20	100.0	20	100.0	6.13	6.14	-0.94	8.04
Week 37 Day 253	n/a	20	100.0	19	95.0	8.20	10.21	0.76	12.82
Week 49 Day 337	n/a	20	100.0	19	95.0	8.20	11.57	1.26	13.80
Week 61 Day 421	n/a	14	70.0	10	71.4	7.10	8.76	-2.80	12.26
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	5.89	7.07	NE	NE
	Moderate	16	80.0	16	100.0	7.37	8.94	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	7.07	2.72	1.18	4.51
	Moderate	16	80.0	16	100.0	6.20	7.06	-1.17	8.36
Week 25 Day 169	Mild	4	20.0	4	100.0	2.36	2.72	-3.54	4.51
	Moderate	16	80.0	16	100.0	7.07	6.44	-0.29	8.69
Week 37 Day 253	Mild	4	20.0	3	75.0	3.14	5.44	-4.71	8.17
	Moderate	16	80.0	16	100.0	9.15	10.73	1.79	13.46
Week 49 Day 337	Mild	4	20.0	3	75.0	0.00	0.00	-4.71	8.17
	Moderate	16	80.0	16	100.0	9.74	12.03	2.38	14.53
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	10	76.9	7.10	8.76	-2.80	12.26
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021


Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_SHRD\_SG.xls

15MAR2022 16:33

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Social Activities (Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=20)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SAHDR\_SG.pdf  
16MAR2022 15:18

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Social Activities (Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Mild (N=4)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SAHRD\_SG.pdf  
16MAR2022 15:18

**POPULATION: Treated Patients Aged 8-17 years**  
**ENDPOINT: CATCH Pediatric: Social Activities (Hard)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SAHDR\_SG.pdf  
16MAR2022 15:18



POPULATION: Treated Patients Aged 8-17 years

ENDPOINT: CATCH Pediatric: School Items

MODEL: --

STUDY: BO41423

Compliance/Mean

		Emicizumab (N=20)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name Visit	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	20	100.0	19	95.0	12.86	8.45	NE	NE
Week 1 Day 1	n/a	20	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	20	100.0	18	90.0	11.18	6.90	-1.29	6.99
Week 25 Day 169	n/a	20	100.0	18	90.0	11.77	16.85	-0.71	16.49
Week 37 Day 253	n/a	20	100.0	15	75.0	17.85	16.22	3.32	13.07
Week 49 Day 337	n/a	20	100.0	18	90.0	12.48	9.33	-0.73	7.74
Week 61 Day 421	n/a	14	70.0	8	57.1	11.96	6.09	-4.26	7.56
Week 73 Day 505	n/a	4	20.0	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	4	20.0	4	100.0	6.60	2.69	NE	NE
	Moderate	16	80.0	15	93.8	14.53	8.72	NE	NE
Week 1 Day 1	Mild	4	20.0	0	0.0	NE	NE	NE	NE
	Moderate	16	80.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	4	20.0	4	100.0	9.08	3.16	2.48	4.95
	Moderate	16	80.0	14	87.5	11.79	7.63	-2.36	7.26
Week 25 Day 169	Mild	4	20.0	4	100.0	6.60	2.69	0.00	4.67
	Moderate	16	80.0	14	87.5	13.24	18.95	-0.91	18.72
Week 37 Day 253	Mild	4	20.0	3	75.0	6.60	3.30	0.00	0.00
	Moderate	16	80.0	12	75.0	20.67	17.02	4.15	14.62
Week 49 Day 337	Mild	4	20.0	3	75.0	5.50	5.04	-1.10	7.62
	Moderate	16	80.0	15	93.8	13.87	9.46	-0.66	8.02
Week 61 Day 421	Mild	1	5.0	0	0.0	NE	NE	NE	NE
	Moderate	13	65.0	8	61.5	11.96	6.09	-4.26	7.56
Week 73 Day 505	Mild	0	0.0	0	0.0	NE	NE	NE	NE
	Moderate	4	20.0	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGE8\_SCHIT\_SG.xls

15MAR2022 16:31

**POPULATION: Treated Patients Aged 8-17 years**


**ENDPOINT: CATCH Pediatric: School Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

All (N=20)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SCHIT\_SG.pdf  
16MAR2022 15:15

**POPULATION: Treated Patients Aged 8-17 years**


**ENDPOINT: CATCH Pediatric: School Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Mild (N=4)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SCHIT\_SG.pdf  
16MAR2022 15:15

**POPULATION: Treated Patients Aged 8-17 years**


**ENDPOINT: CATCH Pediatric: School Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Moderate (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE8\_SCHIT\_SG.pdf  
16MAR2022 15:15

POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: College Items  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	3	7.1	4.89	2.12	NE	NE
Week 1 Day 1	n/a	42	100.0	0	0.0	NE	NE	NE	NE
Week 13 Day 85	n/a	42	100.0	2	4.8	5.50	2.59	0.00	0.00
Week 25 Day 169	n/a	41	97.6	3	7.3	12.22	5.60	7.33	6.35
Week 37 Day 253	n/a	39	92.9	2	5.1	7.33	10.37	1.83	7.78
Week 49 Day 337	n/a	37	88.1	2	5.4	7.33	5.19	1.83	2.59
Week 61 Day 421	n/a	23	54.8	1	4.3	14.67	NE	7.33	NE
Week 73 Day 505	n/a	6	14.3	0	0.0	NE	NE	NE	NE
Week 85 Day 589	n/a	2	4.8	0	0.0	NE	NE	NE	NE
Patient Disposition	n/a	2	4.8	1	50.0	0.00	NE	-3.67	NE
Hemophilia severity									
Baseline	Mild	16	38.1	1	6.3	7.33	NE	NE	NE
	Moderate	26	61.9	2	7.7	3.67	0.00	NE	NE
Week 1 Day 1	Mild	16	38.1	0	0.0	NE	NE	NE	NE
	Moderate	26	61.9	0	0.0	NE	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	1	6.3	7.33	NE	0.00	NE
	Moderate	26	61.9	1	3.8	3.67	NE	0.00	NE
Week 25 Day 169	Mild	15	35.7	1	6.7	11.00	NE	3.67	NE
	Moderate	26	61.9	2	7.7	12.83	7.78	9.17	7.78
Week 37 Day 253	Mild	13	31.0	1	7.7	14.67	NE	7.33	NE
	Moderate	26	61.9	1	3.8	0.00	NE	-3.67	NE
Week 49 Day 337	Mild	12	28.6	1	8.3	11.00	NE	3.67	NE
	Moderate	25	59.5	1	4.0	3.67	NE	0.00	NE
Week 61 Day 421	Mild	5	11.9	1	20.0	14.67	NE	7.33	NE
	Moderate	18	42.9	0	0.0	NE	NE	NE	NE
Week 73 Day 505	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	5	11.9	0	0.0	NE	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	1	2.4	0	0.0	NE	NE	NE	NE
Patient Disposition	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	1	2.4	1	100.0	0.00	NE	-3.67	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: College Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

All (N=42)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_COLGIT\_SG.pdf  
16MAR2022 14:59

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: College Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Mild (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_COLGIT\_SG.pdf  
16MAR2022 14:59

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: College Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_COLGIT\_SG.pdf  
16MAR2022 14:59




POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Daily Activities (Impact)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	40	95.2	23.56	24.09	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	33.87	30.70	NE	NE
Week 13 Day 85	n/a	42	100.0	39	92.9	20.47	19.71	-1.64	10.50
Week 25 Day 169	n/a	41	97.6	40	97.6	22.35	19.80	-1.74	13.71
Week 37 Day 253	n/a	39	92.9	37	94.9	19.64	19.76	-2.68	15.07
Week 49 Day 337	n/a	37	88.1	35	94.6	19.76	19.29	-2.05	16.66
Week 61 Day 421	n/a	23	54.8	11	47.8	13.91	17.13	-8.15	15.33
Week 73 Day 505	n/a	6	14.3	2	33.3	6.08	3.68	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	13.92	7.41	NE	NE
Patient Disposition	n/a	2	4.8	2	100.0	6.95	7.37	-21.84	30.89
Hemophilia severity									
Baseline	Mild	16	38.1	15	93.8	14.26	17.71	NE	NE
	Moderate	26	61.9	25	96.2	29.14	25.95	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	12.16	NE	NE	NE
	Moderate	26	61.9	1	3.8	55.58	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	15	93.8	12.75	13.86	0.24	9.49
	Moderate	26	61.9	24	92.3	25.29	21.49	-2.78	11.12
Week 25 Day 169	Mild	15	35.7	14	93.3	14.05	12.17	0.00	15.25
	Moderate	26	61.9	26	100.0	26.82	21.81	-2.64	13.08
Week 37 Day 253	Mild	13	31.0	11	84.6	10.75	12.31	3.14	4.79
	Moderate	26	61.9	26	100.0	23.41	21.26	-5.00	17.13
Week 49 Day 337	Mild	12	28.6	12	100.0	14.19	14.51	7.11	10.47
	Moderate	25	59.5	23	92.0	22.67	21.08	-6.63	17.45
Week 61 Day 421	Mild	5	11.9	4	80.0	6.95	8.15	0.00	3.01
	Moderate	18	42.9	7	38.9	17.89	20.13	-12.23	17.68
Week 73 Day 505	Mild	1	2.4	1	100.0	8.68	NE	NE	NE
	Moderate	5	11.9	1	20.0	3.47	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	19.16	NE	NE	NE
	Moderate	1	2.4	1	100.0	8.68	NE	NE	NE
Patient Disposition	Mild	1	2.4	1	100.0	12.16	NE	-43.68	NE
	Moderate	1	2.4	1	100.0	1.74	NE	0.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Daily Activities (Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_DAIM\_SG.pdf  
16MAR2022 14:59

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Daily Activities (Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_DAIM\_SG.pdf  
16MAR2022 14:59

**POPULATION:** Treated Patients Aged  $\geq 18$  years  
**ENDPOINT:** CATCH Adult: Daily Activities (Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_DAIM\_SG.pdf  
16MAR2022 14:59


POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Daily Activities (Risky)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	40	95.2	20.93	20.29	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	19.97	13.51	NE	NE
Week 13 Day 85	n/a	42	100.0	39	92.9	17.66	17.45	-1.99	9.07
Week 25 Day 169	n/a	41	97.6	40	97.6	18.69	17.51	-2.22	10.36
Week 37 Day 253	n/a	39	92.9	37	94.9	14.00	13.44	-4.69	11.40
Week 49 Day 337	n/a	37	88.1	35	94.6	17.48	18.02	-1.71	13.00
Week 61 Day 421	n/a	23	54.8	11	47.8	12.00	12.37	-6.20	11.26
Week 73 Day 505	n/a	6	14.3	2	33.3	7.82	1.23	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	13.92	7.41	NE	NE
Patient Disposition	n/a	2	4.8	2	100.0	22.58	29.48	-7.08	5.10
Hemophilia severity									
Baseline	Mild	16	38.1	15	93.8	17.50	16.77	NE	NE
	Moderate	26	61.9	25	96.2	22.99	22.21	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	10.42	NE	NE	NE
	Moderate	26	61.9	1	3.8	29.53	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	15	93.8	13.91	11.48	-1.99	10.76
	Moderate	26	61.9	24	92.3	20.01	20.19	-2.00	8.13
Week 25 Day 169	Mild	15	35.7	14	93.3	16.89	13.69	0.00	10.63
	Moderate	26	61.9	26	100.0	19.66	19.44	-3.37	10.24
Week 37 Day 253	Mild	13	31.0	11	84.6	11.54	8.87	2.44	5.64
	Moderate	26	61.9	26	100.0	15.05	15.00	-7.55	11.94
Week 49 Day 337	Mild	12	28.6	12	100.0	16.66	16.84	6.01	11.10
	Moderate	25	59.5	23	92.0	17.91	18.96	-5.57	12.33
Week 61 Day 421	Mild	5	11.9	4	80.0	13.46	5.56	2.89	6.10
	Moderate	18	42.9	7	38.9	11.17	15.40	-10.75	10.65
Week 73 Day 505	Mild	1	2.4	1	100.0	8.68	NE	NE	NE
	Moderate	5	11.9	1	20.0	6.95	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	19.16	NE	NE	NE
	Moderate	1	2.4	1	100.0	8.68	NE	NE	NE
Patient Disposition	Mild	1	2.4	1	100.0	43.42	NE	-10.68	NE
	Moderate	1	2.4	1	100.0	1.74	NE	-3.47	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Daily Activities (Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_DARIS\_SG.pdf  
16MAR2022 15:01

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Daily Activities (Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_DARIS\_SG.pdf  
16MAR2022 15:01

**POPULATION: Treated Patients Aged >= 18 years**  
**ENDPOINT: CATCH Adult: Daily Activities (Risky)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_DARIS\_SG.pdf  
16MAR2022 15:01




POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Hemophilia Treatment  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	40	95.2	37.09	22.81	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	10.94	6.63	NE	NE
Week 13 Day 85	n/a	42	100.0	39	92.9	24.46	23.04	-11.16	21.06
Week 25 Day 169	n/a	41	97.6	40	97.6	22.73	20.93	-13.52	21.04
Week 37 Day 253	n/a	39	92.9	37	94.9	21.88	20.89	-12.98	21.04
Week 49 Day 337	n/a	37	88.1	35	94.6	26.61	22.76	-9.13	19.25
Week 61 Day 421	n/a	23	54.8	11	47.8	19.32	15.30	-25.69	17.94
Week 73 Day 505	n/a	6	14.3	2	33.3	18.75	22.10	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	3.13	0.00	NE	NE
Patient Disposition	n/a	2	4.8	2	100.0	10.94	15.47	-26.56	11.05
Hemophilia severity									
Baseline	Mild	16	38.1	15	93.8	31.58	20.15	NE	NE
	Moderate	26	61.9	25	96.2	40.39	24.04	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	6.25	NE	NE	NE
	Moderate	26	61.9	1	3.8	15.63	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	15	93.8	21.46	21.42	-8.55	17.93
	Moderate	26	61.9	24	92.3	26.34	24.26	-12.75	23.00
Week 25 Day 169	Mild	15	35.7	14	93.3	23.66	22.92	-6.08	23.82
	Moderate	26	61.9	26	100.0	22.24	20.24	-17.39	18.80
Week 37 Day 253	Mild	13	31.0	11	84.6	18.47	20.03	-4.46	10.32
	Moderate	26	61.9	26	100.0	23.32	21.46	-16.39	23.35
Week 49 Day 337	Mild	12	28.6	12	100.0	20.05	21.38	-3.49	12.77
	Moderate	25	59.5	23	92.0	30.03	23.15	-11.95	21.50
Week 61 Day 421	Mild	5	11.9	4	80.0	22.66	13.35	-15.63	10.83
	Moderate	18	42.9	7	38.9	17.41	17.01	-30.73	19.41
Week 73 Day 505	Mild	1	2.4	1	100.0	34.38	NE	NE	NE
	Moderate	5	11.9	1	20.0	3.13	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	3.13	NE	NE	NE
	Moderate	1	2.4	1	100.0	3.13	NE	NE	NE
Patient Disposition	Mild	1	2.4	1	100.0	21.88	NE	-34.38	NE
	Moderate	1	2.4	1	100.0	0.00	NE	-18.75	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION: Treated Patients Aged >= 18 years**  
**ENDPOINT: CATCH Adult: Hemophilia Treatment**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_HEMTRT\_SG.pdf  
16MAR2022 15:02

**POPULATION:** Treated Patients Aged  $\geq 18$  years  
**ENDPOINT:** CATCH Adult: Hemophilia Treatment  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_HEMTRT\_SG.pdf  
16MAR2022 15:02

**POPULATION: Treated Patients Aged >= 18 years**  
**ENDPOINT: CATCH Adult: Hemophilia Treatment**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_HEMTRT\_SG.pdf  
16MAR2022 15:02


POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Recreational Activities (Do, Impact)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	32	76.2	40.24	25.26	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	33.00	46.67	NE	NE
Week 13 Day 85	n/a	42	100.0	27	64.3	35.06	20.59	-5.39	25.22
Week 25 Day 169	n/a	41	97.6	28	68.3	40.22	26.48	-1.75	30.92
Week 37 Day 253	n/a	39	92.9	25	64.1	34.14	22.08	-6.63	28.33
Week 49 Day 337	n/a	37	88.1	22	59.5	38.90	23.30	0.17	26.17
Week 61 Day 421	n/a	23	54.8	9	39.1	33.61	13.60	-12.25	25.57
Week 73 Day 505	n/a	6	14.3	2	33.3	36.30	42.00	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	24.75	11.67	NE	NE
Patient Disposition	n/a	2	4.8	1	50.0	0.00	NE	-55.00	NE
Hemophilia severity									
Baseline	Mild	16	38.1	13	81.3	23.58	16.00	NE	NE
	Moderate	26	61.9	19	73.1	51.65	24.31	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	0.00	NE	NE	NE
	Moderate	26	61.9	1	3.8	66.00	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	12	75.0	29.10	21.31	6.87	27.41
	Moderate	26	61.9	15	57.7	39.84	19.37	-15.03	19.20
Week 25 Day 169	Mild	15	35.7	10	66.7	36.96	26.65	8.98	31.02
	Moderate	26	61.9	18	69.2	42.04	26.98	-7.79	30.14
Week 37 Day 253	Mild	13	31.0	10	76.9	27.94	28.93	0.67	32.71
	Moderate	26	61.9	15	57.7	38.28	15.88	-11.33	25.29
Week 49 Day 337	Mild	12	28.6	9	75.0	29.33	25.80	7.08	30.79
	Moderate	25	59.5	13	52.0	45.53	19.75	-4.86	22.43
Week 61 Day 421	Mild	5	11.9	3	60.0	27.50	9.53	-0.55	8.56
	Moderate	18	42.9	6	33.3	36.67	15.03	-16.93	29.43
Week 73 Day 505	Mild	1	2.4	1	100.0	66.00	NE	NE	NE
	Moderate	5	11.9	1	20.0	6.60	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	33.00	NE	NE	NE
	Moderate	1	2.4	1	100.0	16.50	NE	NE	NE
Patient Disposition	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	1	2.4	1	100.0	0.00	NE	-55.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Recreational Activities (Do, Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_RADOIM\_SG.pdf  
16MAR2022 15:03

**POPULATION:** Treated Patients Aged  $\geq 18$  years  
**ENDPOINT:** CATCH Adult: Recreational Activities (Do, Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_RADOIM\_SG.pdf  
16MAR2022 15:03

**POPULATION:** Treated Patients Aged  $\geq 18$  years  
**ENDPOINT:** CATCH Adult: Recreational Activities (Do, Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_RADOIM\_SG.pdf  
16MAR2022 15:03




POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Recreational Activities (Do, Risky)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	32	76.2	44.51	21.91	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	38.50	7.78	NE	NE
Week 13 Day 85	n/a	42	100.0	27	64.3	35.90	21.69	-9.29	18.82
Week 25 Day 169	n/a	41	97.6	28	68.3	44.39	22.11	-0.01	23.17
Week 37 Day 253	n/a	39	92.9	25	64.1	38.53	20.96	-9.02	19.90
Week 49 Day 337	n/a	37	88.1	22	59.5	40.98	21.46	-3.43	21.64
Week 61 Day 421	n/a	23	54.8	9	39.1	37.69	27.09	-8.05	21.59
Week 73 Day 505	n/a	6	14.3	2	33.3	42.90	32.67	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	24.75	11.67	NE	NE
Patient Disposition	n/a	2	4.8	1	50.0	16.50	NE	-38.50	NE
Hemophilia severity									
Baseline	Mild	16	38.1	13	81.3	47.80	24.44	NE	NE
	Moderate	26	61.9	19	73.1	42.26	20.37	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	33.00	NE	NE	NE
	Moderate	26	61.9	1	3.8	44.00	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	12	75.0	38.56	26.31	-5.43	20.44
	Moderate	26	61.9	15	57.7	33.77	17.87	-12.33	17.61
Week 25 Day 169	Mild	15	35.7	10	66.7	44.27	22.92	-3.38	23.58
	Moderate	26	61.9	18	69.2	44.45	22.32	1.89	23.48
Week 37 Day 253	Mild	13	31.0	10	76.9	37.94	31.21	-15.20	14.51
	Moderate	26	61.9	15	57.7	38.92	11.25	-5.04	22.29
Week 49 Day 337	Mild	12	28.6	9	75.0	31.17	20.94	-12.84	19.11
	Moderate	25	59.5	13	52.0	47.77	19.78	3.42	21.56
Week 61 Day 421	Mild	5	11.9	3	60.0	33.00	0.00	-17.87	6.32
	Moderate	18	42.9	6	33.3	40.04	33.98	-4.12	24.93
Week 73 Day 505	Mild	1	2.4	1	100.0	66.00	NE	NE	NE
	Moderate	5	11.9	1	20.0	19.80	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	33.00	NE	NE	NE
	Moderate	1	2.4	1	100.0	16.50	NE	NE	NE
Patient Disposition	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	1	2.4	1	100.0	16.50	NE	-38.50	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Recreational Activities (Do, Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_RADORI\_SG.pdf  
16MAR2022 15:03

**POPULATION:** Treated Patients Aged  $\geq 18$  years  
**ENDPOINT:** CATCH Adult: Recreational Activities (Do, Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_RADORI\_SG.pdf  
16MAR2022 15:03

**POPULATION: Treated Patients Aged >= 18 years**  
**ENDPOINT: CATCH Adult: Recreational Activities (Do, Risky)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_RADORI\_SG.pdf  
16MAR2022 15:03


POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Social Activities (Impact)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	40	95.2	26.39	24.22	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	40.59	27.71	NE	NE
Week 13 Day 85	n/a	42	100.0	39	92.9	23.10	21.13	-1.02	12.16
Week 25 Day 169	n/a	41	97.6	40	97.6	25.54	22.53	-1.70	12.80
Week 37 Day 253	n/a	39	92.9	37	94.9	21.26	20.21	-4.16	16.44
Week 49 Day 337	n/a	37	88.1	35	94.6	23.43	22.32	-1.21	18.15
Week 61 Day 421	n/a	23	54.8	11	47.8	16.91	15.02	-14.11	18.21
Week 73 Day 505	n/a	6	14.3	2	33.3	12.00	12.73	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	13.50	2.12	NE	NE
Patient Disposition	n/a	2	4.8	2	100.0	12.00	16.97	-13.64	10.80
Hemophilia severity									
Baseline	Mild	16	38.1	15	93.8	17.22	16.49	NE	NE
	Moderate	26	61.9	25	96.2	31.89	26.66	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	21.00	NE	NE	NE
	Moderate	26	61.9	1	3.8	60.18	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	15	93.8	17.01	17.61	2.77	8.29
	Moderate	26	61.9	24	92.3	26.90	22.58	-3.34	13.66
Week 25 Day 169	Mild	15	35.7	14	93.3	19.32	21.16	0.92	9.28
	Moderate	26	61.9	26	100.0	28.88	22.94	-3.06	14.27
Week 37 Day 253	Mild	13	31.0	11	84.6	14.73	15.90	3.60	10.18
	Moderate	26	61.9	26	100.0	24.02	21.45	-7.27	17.58
Week 49 Day 337	Mild	12	28.6	12	100.0	16.50	18.91	6.55	14.31
	Moderate	25	59.5	23	92.0	27.04	23.48	-5.10	18.90
Week 61 Day 421	Mild	5	11.9	4	80.0	9.00	5.48	-2.00	6.93
	Moderate	18	42.9	7	38.9	21.43	17.18	-20.17	19.48
Week 73 Day 505	Mild	1	2.4	1	100.0	21.00	NE	NE	NE
	Moderate	5	11.9	1	20.0	3.00	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	15.00	NE	NE	NE
	Moderate	1	2.4	1	100.0	12.00	NE	NE	NE
Patient Disposition	Mild	1	2.4	1	100.0	24.00	NE	-21.27	NE
	Moderate	1	2.4	1	100.0	0.00	NE	-6.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Social Activities (Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_SAIMP\_SG.pdf  
16MAR2022 15:04

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Social Activities (Impact)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_SAIMP\_SG.pdf  
16MAR2022 15:04

**POPULATION: Treated Patients Aged >= 18 years**  
**ENDPOINT: CATCH Adult: Social Activities (Impact)**  
**MODEL: --**  
**STUDY: BO41423**  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_SAIMP\_SG.pdf  
16MAR2022 15:04




POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Social Activities (Risky)  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	40	95.2	22.41	19.51	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	22.00	0.00	NE	NE
Week 13 Day 85	n/a	42	100.0	39	92.9	22.59	19.36	1.66	10.55
Week 25 Day 169	n/a	41	97.6	40	97.6	22.39	19.83	-0.79	10.59
Week 37 Day 253	n/a	39	92.9	37	94.9	17.36	17.11	-3.37	12.83
Week 49 Day 337	n/a	37	88.1	35	94.6	19.19	19.28	-1.57	16.57
Week 61 Day 421	n/a	23	54.8	11	47.8	12.67	13.85	-8.58	9.73
Week 73 Day 505	n/a	6	14.3	2	33.3	14.67	5.19	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	16.50	2.59	NE	NE
Patient Disposition	n/a	2	4.8	2	100.0	16.50	23.33	-7.50	10.61
Hemophilia severity									
Baseline	Mild	16	38.1	15	93.8	18.86	14.84	NE	NE
	Moderate	26	61.9	25	96.2	24.54	21.86	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	22.00	NE	NE	NE
	Moderate	26	61.9	1	3.8	22.00	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	15	93.8	21.28	16.14	5.21	8.98
	Moderate	26	61.9	24	92.3	23.40	21.42	-0.50	11.03
Week 25 Day 169	Mild	15	35.7	14	93.3	20.98	16.47	1.12	7.43
	Moderate	26	61.9	26	100.0	23.15	21.69	-1.78	11.93
Week 37 Day 253	Mild	13	31.0	11	84.6	15.00	11.53	2.92	11.71
	Moderate	26	61.9	26	100.0	18.35	19.10	-5.89	12.59
Week 49 Day 337	Mild	12	28.6	12	100.0	18.03	17.72	5.99	15.59
	Moderate	25	59.5	23	92.0	19.80	20.41	-5.35	16.06
Week 61 Day 421	Mild	5	11.9	4	80.0	10.08	8.13	-1.22	5.60
	Moderate	18	42.9	7	38.9	14.14	16.73	-12.26	9.50
Week 73 Day 505	Mild	1	2.4	1	100.0	18.33	NE	NE	NE
	Moderate	5	11.9	1	20.0	11.00	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	18.33	NE	NE	NE
	Moderate	1	2.4	1	100.0	14.67	NE	NE	NE
Patient Disposition	Mild	1	2.4	1	100.0	33.00	NE	-15.00	NE
	Moderate	1	2.4	1	100.0	0.00	NE	0.00	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Social Activities (Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

All (N=42)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_SARIS\_SG.pdf  
16MAR2022 15:05

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Social Activities (Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Mild (N=16)




Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_SARIS\_SG.pdf  
16MAR2022 15:05

**POPULATION:** Treated Patients Aged >= 18 years  
**ENDPOINT:** CATCH Adult: Social Activities (Risky)  
**MODEL:** --  
**STUDY:** BO41423  
**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_SARIS\_SG.pdf  
16MAR2022 15:05

POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Typical Day  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	40	95.2	59.58	29.11	NE	NE
Week 1 Day 1	n/a	42	100.0	2	4.8	54.17	25.53	NE	NE
Week 13 Day 85	n/a	42	100.0	39	92.9	56.05	26.54	-1.58	19.37
Week 25 Day 169	n/a	41	97.6	40	97.6	53.89	23.84	-3.29	18.48
Week 37 Day 253	n/a	39	92.9	37	94.9	51.13	25.63	-5.87	17.08
Week 49 Day 337	n/a	37	88.1	35	94.6	46.98	26.37	-9.01	15.26
Week 61 Day 421	n/a	23	54.8	11	47.8	44.95	19.24	-11.11	24.45
Week 73 Day 505	n/a	6	14.3	2	33.3	45.83	25.53	NE	NE
Week 85 Day 589	n/a	2	4.8	2	100.0	30.56	19.64	NE	NE
Patient Disposition	n/a	2	4.8	2	100.0	58.33	3.93	1.39	5.89
Hemophilia severity									
Baseline	Mild	16	38.1	15	93.8	58.70	28.58	NE	NE
	Moderate	26	61.9	25	96.2	60.11	30.00	NE	NE
Week 1 Day 1	Mild	16	38.1	1	6.3	36.11	NE	NE	NE
	Moderate	26	61.9	1	3.8	72.22	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	15	93.8	56.85	28.85	2.98	19.32
	Moderate	26	61.9	24	92.3	55.56	25.63	-4.35	19.30
Week 25 Day 169	Mild	15	35.7	14	93.3	57.74	24.34	5.34	22.86
	Moderate	26	61.9	26	100.0	51.82	23.79	-7.78	14.28
Week 37 Day 253	Mild	13	31.0	11	84.6	46.97	25.92	-1.11	19.69
	Moderate	26	61.9	26	100.0	52.88	25.81	-7.78	15.96
Week 49 Day 337	Mild	12	28.6	12	100.0	44.91	27.44	-5.56	15.66
	Moderate	25	59.5	23	92.0	48.07	26.36	-10.73	15.12
Week 61 Day 421	Mild	5	11.9	4	80.0	43.75	20.21	-7.41	27.40
	Moderate	18	42.9	7	38.9	45.63	20.28	-12.96	25.38
Week 73 Day 505	Mild	1	2.4	1	100.0	63.89	NE	NE	NE
	Moderate	5	11.9	1	20.0	27.78	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	1	100.0	44.44	NE	NE	NE
	Moderate	1	2.4	1	100.0	16.67	NE	NE	NE
Patient Disposition	Mild	1	2.4	1	100.0	55.56	NE	-2.78	NE
	Moderate	1	2.4	1	100.0	61.11	NE	5.56	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.  
<sup>2</sup> mean: descriptive statistics - absolute values  
<sup>3</sup> mean: descriptive statistics - change from baseline values  
 Clinical cut-off: 30OCT2021

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: Typical Day**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

All (N=42)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPprimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_TYPDAY\_SG.pdf  
16MAR2022 15:07

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: Typical Day**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Mild (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_TYPDAY\_SG.pdf  
16MAR2022 15:07

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: Typical Day**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_TYPDAY\_SG.pdf  
16MAR2022 15:07



POPULATION: Treated Patients Aged >= 18 years  
 ENDPOINT: CATCH Adult: Work Items  
 MODEL: --  
 STUDY: BO41423  
 Compliance/Mean

		Emicizumab (N=42)							
		Patients				Statistics for Score		Statistics for Change from Baseline	
Name	Level	in study <sup>1</sup>	%	with value <sup>1</sup>	%	mean <sup>2</sup>	SD	mean <sup>3</sup>	SD
All									
Baseline	n/a	42	100.0	31	73.8	30.83	25.05	NE	NE
Week 1 Day 1	n/a	42	100.0	1	2.4	36.67	NE	NE	NE
Week 13 Day 85	n/a	42	100.0	31	73.8	20.96	21.00	-4.76	20.34
Week 25 Day 169	n/a	41	97.6	32	78.0	28.72	27.23	-0.89	19.39
Week 37 Day 253	n/a	39	92.9	30	76.9	30.18	31.31	0.00	22.55
Week 49 Day 337	n/a	37	88.1	27	73.0	27.24	26.57	-4.88	17.48
Week 61 Day 421	n/a	23	54.8	9	39.1	17.93	16.85	-14.71	11.99
Week 73 Day 505	n/a	6	14.3	1	16.7	0.00	NE	NE	NE
Week 85 Day 589	n/a	2	4.8	1	50.0	29.33	NE	NE	NE
Patient Disposition	n/a	2	4.8	0	0.0	NE	NE	NE	NE
Hemophilia severity									
Baseline	Mild	16	38.1	13	81.3	27.99	27.82	NE	NE
	Moderate	26	61.9	18	69.2	32.88	23.46	NE	NE
Week 1 Day 1	Mild	16	38.1	0	0.0	NE	NE	NE	NE
	Moderate	26	61.9	1	3.8	36.67	NE	NE	NE
Week 13 Day 85	Mild	16	38.1	12	75.0	23.25	23.52	-1.88	17.73
	Moderate	26	61.9	19	73.1	19.51	19.78	-6.92	22.42
Week 25 Day 169	Mild	15	35.7	11	73.3	36.48	33.88	11.74	17.16
	Moderate	26	61.9	21	80.8	24.66	22.91	-8.60	16.73
Week 37 Day 253	Mild	13	31.0	8	61.5	29.92	36.28	5.51	15.70
	Moderate	26	61.9	22	84.6	30.27	30.26	-2.45	25.02
Week 49 Day 337	Mild	12	28.6	9	75.0	31.10	36.06	4.52	16.34
	Moderate	25	59.5	18	72.0	25.31	21.36	-10.53	16.08
Week 61 Day 421	Mild	5	11.9	3	60.0	20.78	20.19	-4.93	5.59
	Moderate	18	42.9	6	33.3	16.50	16.84	-22.06	9.96
Week 73 Day 505	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	5	11.9	1	20.0	0.00	NE	NE	NE
Week 85 Day 589	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	1	2.4	1	100.0	29.33	NE	NE	NE
Patient Disposition	Mild	1	2.4	0	0.0	NE	NE	NE	NE
	Moderate	1	2.4	0	0.0	NE	NE	NE	NE

<sup>1</sup> in study: number of subjects in study at respective visit; % based on baseline.  
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.

<sup>2</sup> mean: descriptive statistics - absolute values

<sup>3</sup> mean: descriptive statistics - change from baseline values

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_DEC21\_TRTGB18\_WORKIT\_SG.xls  
 15MAR2022 16:25

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: Work Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

All (N=42)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_WORKIT\_SG.pdf  
16MAR2022 15:07

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: Work Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Mild (N=16)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_WORKIT\_SG.pdf  
16MAR2022 15:07

**POPULATION: Treated Patients Aged >= 18 years**


**ENDPOINT: CATCH Adult: Work Items**

**MODEL: --**

**STUDY: BO41423**

**Mean Plot**

Hemophilia severity: Moderate (N=26)



Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/g\_eff\_mean.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/g\_eff\_mean\_DEC21\_TRTGE18\_WORKIT\_SG.pdf  
16MAR2022 15:07

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Treatments Prefer Child to Take  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)															
		All responding patients				Prefer the new study drug treatment (SC)				Prefer my old hemophilia Treatment (IV)				Have no preference			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL	n	%	95% Lower CL	95% Upper CL	n	%	95% Lower CL	95% Upper CL		
All																	
Week 17 Day 113	n/a	52	92.9	50	96.2	86.79	99.53	1	1.9	0.05	10.26	1	1.9	0.05	10.26		
Hemophilia severity																	
Week 17 Day 113	Mild	17	30.4	15	88.2	63.56	98.54	1	5.9	0.15	28.69	1	5.9	0.15	28.69		
	Moderate	35	62.5	35	100.0	90.00	100.00	0	0.0	0.00	10.00	0	0.0	0.00	10.00		

95% CI for one sample binomial using Pearson-Clopper method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc\_DEC21\_TRTGE12\_PEPREF\_SG.xls  
 17MAR2022 12:48

POPULATION: Treated Patients Aged >= 12 years

ENDPOINT: Emicizumab Preference Survey: Route of administration (IV or SC) was easier

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	14	28.0	30	60.0	47	94.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	7	46.7	12	80.0	14	93.3
	Moderate	35	62.5	7	20.0	18	51.4	33	94.3

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP2\_SG.xls

17MAR2022 12:50

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Pain associated with treatment was less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	2	4.0	9	18.0	30	60.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	2	13.3	8	53.3
	Moderate	35	62.5	2	5.7	7	20.0	22	62.9

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP3\_SG.xls  
 17MAR2022 12:51

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Worry about finding a vein was less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	2	4.0	9	18.0	39	78.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	5	33.3	14	93.3
	Moderate	35	62.5	2	5.7	4	11.4	25	71.4

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP4\_SG.xls  
 17MAR2022 12:52



POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Concern over port use/infection was less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	0	0.0	3	6.0	22	44.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	0	0.0	8	53.3
	Moderate	35	62.5	0	0.0	3	8.6	14	40.0

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP5\_SG.xls  
 17MAR2022 12:53

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Administration was easier  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	8	16.0	17	34.0	44	88.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	3	20.0	6	40.0	14	93.3
	Moderate	35	62.5	5	14.3	11	31.4	30	85.7

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP6\_SG.xls  
 17MAR2022 12:54

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Able to keep treatment at room temperature  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	0	0.0	4	8.0	21	42.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	1	6.7	7	46.7
	Moderate	35	62.5	0	0.0	3	8.6	14	40.0

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP7\_SG.xls  
 17MAR2022 12:55

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Time to administer treatment was shorter  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	0	0.0	11	22.0	40	80.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	4	26.7	11	73.3
	Moderate	35	62.5	0	0.0	7	20.0	29	82.9

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP8\_SG.xls  
 17MAR2022 12:56

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: The frequency of treatments was lower  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	11	22.0	15	30.0	40	80.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	4	26.7	5	33.3	11	73.3
	Moderate	35	62.5	7	20.0	10	28.6	29	82.9

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP9\_SG.xls  
 17MAR2022 12:57

POPULATION: Treated Patients Aged >= 12 years

ENDPOINT: Emicizumab Preference Survey: Effect on other activities (work, school, sports, social interactions) was less

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	2	4.0	10	20.0	33	66.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	2	13.3	10	66.7
	Moderate	35	62.5	2	5.7	8	22.9	23	65.7

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP10\_SG.xls

17MAR2022 12:58

POPULATION: Treated Patients Aged >= 12 years

ENDPOINT: Emicizumab Preference Survey: Impact on family members and friends was less

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	0	0.0	3	6.0	27	54.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	0	0.0	8	53.3
	Moderate	35	62.5	0	0.0	3	8.6	19	54.3

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP11\_SG.xls

17MAR2022 12:59

POPULATION: Treated Patients Aged >= 12 years

ENDPOINT: Emicizumab Preference Survey: Worries about having a bleed were less

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	7	14.0	13	26.0	38	76.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	1	6.7	4	26.7	13	86.7
	Moderate	35	62.5	6	17.1	9	25.7	25	71.4

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP12\_SG.xls

17MAR2022 13:00



POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Quality of life, in general, was better  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	3	6.0	17	34.0	44	88.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	3	20.0	13	86.7
	Moderate	35	62.5	3	8.6	14	40.0	31	88.6

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP13\_SG.xls  
 17MAR2022 13:01

POPULATION: Treated Patients Aged >= 12 years

ENDPOINT: Emicizumab Preference Survey: It was easier to take every dose my doctor recommended

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	0	0.0	2	4.0	38	76.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	0	0.0	11	73.3
	Moderate	35	62.5	0	0.0	2	5.7	27	77.1

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP14\_SG.xls

17MAR2022 13:02

POPULATION: Treated Patients Aged >= 12 years  
 ENDPOINT: Emicizumab Preference Survey: Made me feel more 'normal'  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=56)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	50	89.3	1	2.0	7	14.0	32	64.0
Hemophilia severity									
Week 17 Day 113	Mild	15	26.8	0	0.0	1	6.7	10	66.7
	Moderate	35	62.5	1	2.9	6	17.1	22	62.9

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTGE12\_PEP15\_SG.xls  
 17MAR2022 13:03

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Treatments Prefer Child to Take  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)															
		All responding patients				Prefer the new study drug treatment (SC)				Prefer my child's old hemophilia Treatment (IV)				Have no preference			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL	n	%	95% Lower CL	95% Upper CL	n	%	95% Lower CL	95% Upper CL		
All																	
Week 17 Day 113	n/a	28	93.3	24	85.7	67.33	95.97	1	3.6	0.09	18.35	3	10.7	2.27	28.23		
Hemophilia severity																	
Week 17 Day 113	Mild	4	13.3	3	75.0	19.41	99.37	0	0.0	0.00	60.24	1	25.0	0.63	80.59		
	Moderate	24	80.0	21	87.5	67.64	97.34	1	4.2	0.11	21.12	2	8.3	1.03	27.00		

95% CI for one sample binomial using Pearson-Clopper method.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc\_DEC21\_TRTLT18\_CEPREF\_SG.xls  
 17MAR2022 12:49

POPULATION: Treated Patients Aged < 18 years (Caregivers)

ENDPOINT: Emicizumab Preference Survey: Route of administration (IV or SC) was easier

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	7	29.2	15	62.5	23	95.8
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	1	33.3	2	66.7	3	100.0
	Moderate	21	70.0	6	28.6	13	61.9	20	95.2

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP2\_SG.xls

17MAR2022 13:04

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Pain associated with treatment was less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	1	4.2	5	20.8	17	70.8
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	1	33.3	3	100.0
	Moderate	21	70.0	1	4.8	4	19.0	14	66.7

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP3\_SG.xls  
 17MAR2022 13:05

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Worry about finding a vein was less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name Visit	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	5	20.8	7	29.2	23	95.8
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	1	33.3	1	33.3	3	100.0
	Moderate	21	70.0	4	19.0	6	28.6	20	95.2

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP4\_SG.xls  
 17MAR2022 13:06

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Concern over port use/infection was less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	0	0.0	2	8.3	15	62.5
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	2	66.7
	Moderate	21	70.0	0	0.0	2	9.5	13	61.9

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP5\_SG.xls  
 17MAR2022 13:07



POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Administration was easier  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	1	4.2	8	33.3	24	100.0
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	2	66.7	3	100.0
	Moderate	21	70.0	1	4.8	6	28.6	21	100.0

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP6\_SG.xls  
 17MAR2022 13:09

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Able to keep treatment at room temperature  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	1	4.2	1	4.2	8	33.3
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	1	33.3	1	33.3	3	100.0
	Moderate	21	70.0	0	0.0	0	0.0	5	23.8

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP7\_SG.xls  
 17MAR2022 13:10

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Time to administer treatment was shorter  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	0	0.0	4	16.7	22	91.7
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	1	33.3	3	100.0
	Moderate	21	70.0	0	0.0	3	14.3	19	90.5

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP8\_SG.xls  
 17MAR2022 13:11

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: The frequency of treatments was lower  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	2	8.3	7	29.2	18	75.0
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	1	33.3	3	100.0
	Moderate	21	70.0	2	9.5	6	28.6	15	71.4

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP9\_SG.xls  
 17MAR2022 13:12

POPULATION: Treated Patients Aged < 18 years (Caregivers)

ENDPOINT: Emicizumab Preference Survey: Effect on other activities (work, school, sports, social interactions) was less

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	1	4.2	4	16.7	18	75.0
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	3	100.0
	Moderate	21	70.0	1	4.8	4	19.0	15	71.4

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP10\_SG.xls

17MAR2022 13:13

POPULATION: Treated Patients Aged < 18 years (Caregivers)

ENDPOINT: Emicizumab Preference Survey: Impact on family members and friends was less

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	0	0.0	1	4.2	21	87.5
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	3	100.0
	Moderate	21	70.0	0	0.0	1	4.8	18	85.7

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP11\_SG.xls

17MAR2022 13:14

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Worries about having a bleed were less  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name Visit	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	5	20.8	11	45.8	20	83.3
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	3	100.0
	Moderate	21	70.0	5	23.8	11	52.4	17	81.0

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP12\_SG.xls  
 17MAR2022 13:15

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Quality of life, in general, was better  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	0	0.0	5	20.8	24	100.0
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	3	100.0
	Moderate	21	70.0	0	0.0	5	23.8	21	100.0

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP13\_SG.xls  
 17MAR2022 13:16



POPULATION: Treated Patients Aged < 18 years (Caregivers)

ENDPOINT: Emicizumab Preference Survey: It was easier to take every dose my doctor recommended

MODEL: --

STUDY: BO41423

Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	0	0.0	0	0.0	17	70.8
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	3	100.0
	Moderate	21	70.0	0	0.0	0	0.0	14	66.7

Corresponding Patients: patients who preferred the new treatment.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP14\_SG.xls

17MAR2022 13:16

POPULATION: Treated Patients Aged < 18 years (Caregivers)  
 ENDPOINT: Emicizumab Preference Survey: Made me feel more 'normal'  
 MODEL: --  
 STUDY: BO41423  
 Descriptive Analysis

		Emicizumab (N=30)							
		Corresponding patients		Most important		Top 3 important		Influenced preference	
Name	Level	n	%	n	%	n	%	n	%
All									
Week 17 Day 113	n/a	24	80.0	1	4.2	2	8.3	20	83.3
Hemophilia severity									
Week 17 Day 113	Mild	3	10.0	0	0.0	0	0.0	3	100.0
	Moderate	21	70.0	1	4.8	2	9.5	17	81.0

Corresponding Patients: patients who preferred the new treatment.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/eff\_mean\_desc2.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/eff\_mean\_desc2\_DEC21\_TRTLT18\_CEP15\_SG.xls  
 17MAR2022 13:17

POPULATION: All Treated Patients

ENDPOINT: Any AEs

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	60	83.3	73.09	90.20
Hemophilia severity	Mild	21	29.2	18	85.7	65.36	95.02
	Moderate	51	70.8	42	82.4	69.75	90.43

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEALL\_SG.xls

21MAR2022 10:41

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade 1**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	35	48.6	37.43	59.93
Hemophilia severity	Mild	21	29.2	10	47.6	28.34	67.63
	Moderate	51	70.8	25	49.0	35.86	62.32

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR1\_SG.xls  
 21MAR2022 10:46

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade 2**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	21	29.2	19.94	40.51
Hemophilia severity	Mild	21	29.2	7	33.3	17.19	54.63
	Moderate	51	70.8	14	27.5	17.11	40.95

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR2\_SG.xls  
 21MAR2022 10:47

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade 3**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	3	4.2	1.43	11.55
Hemophilia severity	Mild	21	29.2	1	4.8	0.85	22.67
	Moderate	51	70.8	2	3.9	1.08	13.22

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR3\_SG.xls  
 21MAR2022 10:47

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade 4**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	1	1.4	0.25	7.46
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR4\_SG.xls  
 21MAR2022 10:52

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade >= 3**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	4	5.6	2.18	13.43
Hemophilia severity	Mild	21	29.2	1	4.8	0.85	22.67
	Moderate	51	70.8	3	5.9	2.02	15.92

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR35\_SG.xls  
 21MAR2022 10:48



**POPULATION: All Treated Patients**  
**ENDPOINT: Any SAEs**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	8	11.1	5.74	20.42
Hemophilia severity	Mild	21	29.2	2	9.5	2.65	28.91
	Moderate	51	70.8	6	11.8	5.51	23.38

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESAE\_SG.xls  
 21MAR2022 10:55

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs leading to treatment discontinuation**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEDIS\_SG.xls  
 21MAR2022 10:43

POPULATION: All Treated Patients  
 ENDPOINT: Any AEs  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% Lower CL	95% Upper CL
All	BLOOD AND LYMPHATIC SYSTEM DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		IRON DEFICIENCY ANAEMIA	n/a	72	100.0	1	1.4	0.25	7.46
	EAR AND LABYRINTH DISORDERS	-Total	n/a	72	100.0	4	5.6	2.18	13.43
		CERUMEN IMPACTION	n/a	72	100.0	1	1.4	0.25	7.46
		EAR PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		OTORRHOEA	n/a	72	100.0	1	1.4	0.25	7.46
		VERTIGO	n/a	72	100.0	1	1.4	0.25	7.46
	EYE DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		UVEITIS	n/a	72	100.0	1	1.4	0.25	7.46
	GASTROINTESTINAL DISORDERS	-Total	n/a	72	100.0	21	29.2	19.94	40.51
		ABDOMINAL PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		ABDOMINAL PAIN UPPER	n/a	72	100.0	3	4.2	1.43	11.55
		COLITIS ULCERATIVE	n/a	72	100.0	1	1.4	0.25	7.46
		DIARRHOEA	n/a	72	100.0	3	4.2	1.43	11.55
		FOOD POISONING	n/a	72	100.0	1	1.4	0.25	7.46
		GASTRITIS	n/a	72	100.0	2	2.8	0.77	9.57
		GASTROINTESTINAL DISORDER	n/a	72	100.0	1	1.4	0.25	7.46
		GASTROESOPHAGEAL REFLUX DISEASE	n/a	72	100.0	3	4.2	1.43	11.55
		HAEMORRHOIDS	n/a	72	100.0	1	1.4	0.25	7.46
		HAEMORRHOIDS THROMBOSED	n/a	72	100.0	1	1.4	0.25	7.46
		HIATUS HERNIA	n/a	72	100.0	1	1.4	0.25	7.46
		LARGE INTESTINE POLYP	n/a	72	100.0	1	1.4	0.25	7.46
		MALLORY-WEISS SYNDROME	n/a	72	100.0	2	2.8	0.77	9.57
		MELAENA	n/a	72	100.0	1	1.4	0.25	7.46
		NAUSEA	n/a	72	100.0	1	1.4	0.25	7.46
		TOOTHACHE	n/a	72	100.0	2	2.8	0.77	9.57
		VOMITING	n/a	72	100.0	3	4.2	1.43	11.55
	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	-Total	n/a	72	100.0	21	29.2	19.94	40.51
		ASTHENIA	n/a	72	100.0	1	1.4	0.25	7.46
		CHEST PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		CHILLS	n/a	72	100.0	1	1.4	0.25	7.46
		FATIGUE	n/a	72	100.0	3	4.2	1.43	11.55
		GRANULOMA	n/a	72	100.0	1	1.4	0.25	7.46
		IMPAIRED HEALING	n/a	72	100.0	1	1.4	0.25	7.46
		INFLUENZA LIKE ILLNESS	n/a	72	100.0	1	1.4	0.25	7.46

		INJECTION SITE IRRITATION	n/a	72	100.0	1	1.4	0.25	7.46
		INJECTION SITE REACTION	n/a	72	100.0	12	16.7	9.80	26.91
		MALaise	n/a	72	100.0	2	2.8	0.77	9.57
		MASS	n/a	72	100.0	1	1.4	0.25	7.46
		PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		PERIPHERAL SWELLING	n/a	72	100.0	2	2.8	0.77	9.57
		PYREXIA	n/a	72	100.0	3	4.2	1.43	11.55
	IMMUNE SYSTEM DISORDERS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		ALLERGY TO CHEMICALS	n/a	72	100.0	1	1.4	0.25	7.46
		SEASONAL ALLERGY	n/a	72	100.0	1	1.4	0.25	7.46
	INFECTIONS AND INFESTATIONS	-Total	n/a	72	100.0	24	33.3	23.53	44.82
		ASYMPTOMATIC COVID-19	n/a	72	100.0	1	1.4	0.25	7.46
		COVID-19	n/a	72	100.0	5	6.9	3.00	15.25
		CYSTITIS	n/a	72	100.0	1	1.4	0.25	7.46
		DIVERTICULITIS	n/a	72	100.0	1	1.4	0.25	7.46
		EPIDIDYMITIS	n/a	72	100.0	1	1.4	0.25	7.46
		ERYSIPELAS	n/a	72	100.0	1	1.4	0.25	7.46
		FEBRILE INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
		FUNGAL SKIN INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
		GASTRIC ULCER HELICOBACTER	n/a	72	100.0	1	1.4	0.25	7.46
		GASTROINTESTINAL INFECTION	n/a	72	100.0	2	2.8	0.77	9.57
		IMPETIGO	n/a	72	100.0	1	1.4	0.25	7.46
		INFECTED DERMAL CYST	n/a	72	100.0	1	1.4	0.25	7.46
		INFLUENZA	n/a	72	100.0	3	4.2	1.43	11.55
		LOWER RESPIRATORY TRACT INFECTION	n/a	72	100.0	2	2.8	0.77	9.57
		NASOPHARYNGITIS	n/a	72	100.0	5	6.9	3.00	15.25
		ORAL HERPES	n/a	72	100.0	1	1.4	0.25	7.46
		RHINITIS	n/a	72	100.0	3	4.2	1.43	11.55
		UPPER RESPIRATORY TRACT INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
		URINARY TRACT INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	17	23.6	15.30	34.60
		ACCIDENTAL OVERDOSE	n/a	72	100.0	1	1.4	0.25	7.46
		CHEST INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		CLOSED GLOBE INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		CONCUSSION	n/a	72	100.0	1	1.4	0.25	7.46
		CONTUSION	n/a	72	100.0	1	1.4	0.25	7.46
		FALL	n/a	72	100.0	4	5.6	2.18	13.43
		FOREIGN BODY IN GASTROINTESTINAL TRACT	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT DISLOCATION	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT INJURY	n/a	72	100.0	2	2.8	0.77	9.57
		LIGAMENT SPRAIN	n/a	72	100.0	2	2.8	0.77	9.57
		LIMB INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		LIP INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		MUSCLE STRAIN	n/a	72	100.0	1	1.4	0.25	7.46
		RIB FRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
		SCRATCH	n/a	72	100.0	1	1.4	0.25	7.46

		SOFT TISSUE INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		THERMAL BURN	n/a	72	100.0	1	1.4	0.25	7.46
		TOOTH FRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
		WRIST FRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
	INVESTIGATIONS	-Total	n/a	72	100.0	6	8.3	3.88	17.01
		ALANINE AMINOTRANSFERASE INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
		ASPARTATE AMINOTRANSFERASE INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
		BLOOD PHOSPHORUS DECREASED	n/a	72	100.0	1	1.4	0.25	7.46
		BLOOD PRESSURE INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
		CARDIAC MURMUR	n/a	72	100.0	1	1.4	0.25	7.46
		HEPATIC ENZYME INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
		PLATELET COUNT DECREASED	n/a	72	100.0	1	1.4	0.25	7.46
	METABOLISM AND NUTRITION DISORDERS	-Total	n/a	72	100.0	3	4.2	1.43	11.55
		HYPERGLYCAEMIA	n/a	72	100.0	2	2.8	0.77	9.57
		VITAMIN D DEFICIENCY	n/a	72	100.0	2	2.8	0.77	9.57
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	-Total	n/a	72	100.0	22	30.6	21.13	41.95
		ARTHRALGIA	n/a	72	100.0	11	15.3	8.75	25.32
		ARTHROPATHY	n/a	72	100.0	1	1.4	0.25	7.46
		BACK PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		BURSITIS	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT CONTRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT EFFUSION	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT STIFFNESS	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT SWELLING	n/a	72	100.0	1	1.4	0.25	7.46
		MUSCULOSKELETAL DISCOMFORT	n/a	72	100.0	1	1.4	0.25	7.46
		MUSCULOSKELETAL STIFFNESS	n/a	72	100.0	1	1.4	0.25	7.46
		MYALGIA	n/a	72	100.0	1	1.4	0.25	7.46
		NECK PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		OSTEOARTHRITIS	n/a	72	100.0	2	2.8	0.77	9.57
		PAIN IN EXTREMITY	n/a	72	100.0	5	6.9	3.00	15.25
		SYNOVIAL CYST	n/a	72	100.0	1	1.4	0.25	7.46
		TENDONITIS	n/a	72	100.0	1	1.4	0.25	7.46
	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		SKIN PAPILLOMA	n/a	72	100.0	1	1.4	0.25	7.46
	NERVOUS SYSTEM DISORDERS	-Total	n/a	72	100.0	14	19.4	11.95	30.03
		HEAD DISCOMFORT	n/a	72	100.0	1	1.4	0.25	7.46
		HEADACHE	n/a	72	100.0	12	16.7	9.80	26.91
		LETHARGY	n/a	72	100.0	1	1.4	0.25	7.46
		MORTON'S NEURALGIA	n/a	72	100.0	1	1.4	0.25	7.46
	PSYCHIATRIC DISORDERS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		ANXIETY	n/a	72	100.0	1	1.4	0.25	7.46
		DEPRESSION	n/a	72	100.0	1	1.4	0.25	7.46

	RENAL AND URINARY DISORDERS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		RENAL COLIC	n/a	72	100.0	2	2.8	0.77	9.57
	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	-Total	n/a	72	100.0	3	4.2	1.43	11.55
		HAEMATOSPERMIA	n/a	72	100.0	1	1.4	0.25	7.46
		PENILE BLISTER	n/a	72	100.0	1	1.4	0.25	7.46
		TESTICULAR PAIN	n/a	72	100.0	1	1.4	0.25	7.46
	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	-Total	n/a	72	100.0	8	11.1	5.74	20.42
		COUGH	n/a	72	100.0	2	2.8	0.77	9.57
		DYSPNOEA	n/a	72	100.0	1	1.4	0.25	7.46
		OROPHARYNGEAL PAIN	n/a	72	100.0	3	4.2	1.43	11.55
		RHINITIS ALLERGIC	n/a	72	100.0	1	1.4	0.25	7.46
		RHINORRHOEA	n/a	72	100.0	1	1.4	0.25	7.46
		SLEEP APNOEA SYNDROME	n/a	72	100.0	1	1.4	0.25	7.46
	SKIN AND SUBCUTANEOUS TISSUE DISORDERS	-Total	n/a	72	100.0	11	15.3	8.75	25.32
		ACNE	n/a	72	100.0	1	1.4	0.25	7.46
		DERMATITIS ALLERGIC	n/a	72	100.0	3	4.2	1.43	11.55
		ECZEMA	n/a	72	100.0	3	4.2	1.43	11.55
		ERYTHEMA	n/a	72	100.0	2	2.8	0.77	9.57
		HENOCH-SCHONLEIN PURPURA	n/a	72	100.0	1	1.4	0.25	7.46
		RASH ERYTHEMATOUS	n/a	72	100.0	1	1.4	0.25	7.46
		RASH PRURITIC	n/a	72	100.0	1	1.4	0.25	7.46
	VASCULAR DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		HYPERTENSION	n/a	72	100.0	1	1.4	0.25	7.46

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEALL\_SG.xls

21MAR2022 11:25

POPULATION: All Treated Patients  
 ENDPOINT: Any AEs  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	BLOOD AND LYMPHATIC SYSTEM DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		IRON DEFICIENCY ANAEMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	EAR AND LABYRINTH DISORDERS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	2	3.9	1.08	13.22
		CERUMEN IMPACTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		EAR PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		OTORRHOEA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		VERTIGO	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	EYE DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		UVEITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	GASTROINTESTINAL DISORDERS	-Total	Mild	21	29.2	7	33.3	17.19	54.63
			Moderate	51	70.8	14	27.5	17.11	40.95
		ABDOMINAL PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		ABDOMINAL PAIN UPPER	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
		COLITIS ULCERATIVE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		DIARRHOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		FOOD POISONING	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTRITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		GASTROINTESTINAL DISORDER	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTROESOPHAGEAL REFLUX DISEASE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
		HAEMORRHOIDS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00

		HAEMORRHOIDS THROMBOSED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		HIATUS HERNIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		LARGE INTESTINE POLYP	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		MALLORY-WEISS SYNDROME	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		MELAENA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		NAUSEA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		TOOTHACHE	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
		VOMITING	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	-Total	Mild	21	29.2	6	28.6	13.81	49.96
			Moderate	51	70.8	15	29.4	18.71	43.00
		ASTHENIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CHEST PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CHILLS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		FATIGUE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		GRANULOMA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		IMPAIRED HEALING	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INFLUENZA LIKE ILLNESS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INJECTION SITE IRRITATION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INJECTION SITE REACTION	Mild	21	29.2	4	19.0	7.67	40.00
			Moderate	51	70.8	8	15.7	8.17	28.01
		MALaise	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		MASS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		PERIPHERAL SWELLING	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		PYREXIA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
	IMMUNE SYSTEM DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		ALLERGY TO CHEMICALS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00



		SEASONAL ALLERGY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INFECTIONS AND INFESTATIONS	-Total	Mild	21	29.2	5	23.8	10.63	45.09
			Moderate	51	70.8	19	37.3	25.32	50.97
		ASYMPTOMATIC COVID-19	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		COVID-19	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	5	9.8	4.26	20.98
		CYSTITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		DIVERTICULITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		EPIDIDYMITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		ERYSIPELAS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FEBRILE INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FUNGAL SKIN INFECTION	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		GASTRIC ULCER HELICOBACTER	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		GASTROINTESTINAL INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		IMPETIGO	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INFECTED DERMAL CYST	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		INFLUENZA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		LOWER RESPIRATORY TRACT INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		NASOPHARYNGITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	5	9.8	4.26	20.98
		ORAL HERPES	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RHINITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		UPPER RESPIRATORY TRACT INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		URINARY TRACT INFECTION	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	15	29.4	18.71	43.00
		ACCIDENTAL OVERDOSE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CHEST INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CLOSED GLOBE INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30

		CONCUSSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CONTUSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FALL	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	3	5.9	2.02	15.92
		FOREIGN BODY IN GASTROINTESTINAL TRACT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		JOINT DISLOCATION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		JOINT INJURY	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
		LIGAMENT SPRAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		LIMB INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		LIP INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MUSCLE STRAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RIB FRACTURE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SCRATCH	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SOFT TISSUE INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		THERMAL BURN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		TOOTH FRACTURE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		WRIST FRACTURE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INVESTIGATIONS	-Total	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	3	5.9	2.02	15.92
		ALANINE AMINOTRANSFERASE INCREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		ASPARTATE AMINOTRANSFERASE INCREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		BLOOD PHOSPHORUS DECREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		BLOOD PRESSURE INCREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		CARDIAC MURMUR	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HEPATIC ENZYME INCREASED	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PLATELET COUNT DECREASED	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	1	2.0	0.35	10.30
	METABOLISM AND NUTRITION DISORDERS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	1	2.0	0.35	10.30
		HYPERGLYCAEMIA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		VITAMIN D DEFICIENCY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	-Total	Mild	21	29.2	9	42.9	24.47	63.45
			Moderate	51	70.8	13	25.5	15.55	38.87
		ARTHRALGIA	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	8	15.7	8.17	28.01
		ARTHROPATHY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		BACK PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		BURSITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		JOINT CONTRACTURE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		JOINT EFFUSION	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		JOINT STIFFNESS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		JOINT SWELLING	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		MUSCULOSKELETAL DISCOMFORT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MUSCULOSKELETAL STIFFNESS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MYALGIA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		NECK PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		OSTEOARTHRITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		PAIN IN EXTREMITY	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	3	5.9	2.02	15.92
		SYNOVIAL CYST	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		TENDONITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SKIN PAPILLOMA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	NERVOUS SYSTEM DISORDERS	-Total	Mild	21	29.2	5	23.8	10.63	45.09
			Moderate	51	70.8	9	17.6	9.57	30.25
		HEAD DISCOMFORT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HEADACHE	Mild	21	29.2	4	19.0	7.67	40.00

			Moderate	51	70.8	8	15.7	8.17	28.01
		LETHARGY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		MORTON'S NEURALGIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	PSYCHIATRIC DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		ANXIETY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		DEPRESSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	RENAL AND URINARY DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		RENAL COLIC	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
		HAEMATOSPERMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PENILE BLISTER	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		TESTICULAR PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	7	13.7	6.81	25.72
		COUGH	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		DYSPNOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		OROPHARYNGEAL PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		RHINITIS ALLERGIC	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RHINORRHOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SLEEP APNOEA SYNDROME	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	SKIN AND SUBCUTANEOUS TISSUE DISORDERS	-Total	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	8	15.7	8.17	28.01
		ACNE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		DERMATITIS ALLERGIC	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	1	2.0	0.35	10.30
		ECZEMA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		ERYTHEMA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		HENOCH-SCHONLEIN PURPURA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RASH ERYTHEMATOUS	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	1	2.0	0.35	10.30
		RASH PRURITIC	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	VASCULAR DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HYPERTENSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.  
Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEALL\_SG.xls  
21MAR2022 11:25

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 1  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% Lower CL	95% Upper CL
All	BLOOD AND LYMPHATIC SYSTEM DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		IRON DEFICIENCY ANAEMIA	n/a	72	100.0	1	1.4	0.25	7.46
	EAR AND LABYRINTH DISORDERS	-Total	n/a	72	100.0	4	5.6	2.18	13.43
		CERUMEN IMPACTION	n/a	72	100.0	1	1.4	0.25	7.46
		EAR PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		OTORRHOEA	n/a	72	100.0	1	1.4	0.25	7.46
		VERTIGO	n/a	72	100.0	1	1.4	0.25	7.46
	EYE DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		UVEITIS	n/a	72	100.0	1	1.4	0.25	7.46
	GASTROINTESTINAL DISORDERS	-Total	n/a	72	100.0	15	20.8	13.05	31.57
		ABDOMINAL PAIN UPPER	n/a	72	100.0	3	4.2	1.43	11.55
		DIARRHOEA	n/a	72	100.0	2	2.8	0.77	9.57
		FOOD POISONING	n/a	72	100.0	1	1.4	0.25	7.46
		GASTRITIS	n/a	72	100.0	1	1.4	0.25	7.46
		GASTROINTESTINAL DISORDER	n/a	72	100.0	1	1.4	0.25	7.46
		GASTROESOPHAGEAL REFLUX DISEASE	n/a	72	100.0	2	2.8	0.77	9.57
		HAEMORRHOIDS	n/a	72	100.0	1	1.4	0.25	7.46
		HAEMORRHOIDS THROMBOSED	n/a	72	100.0	1	1.4	0.25	7.46
		HIATUS HERNIA	n/a	72	100.0	1	1.4	0.25	7.46
		LARGE INTESTINE POLYP	n/a	72	100.0	1	1.4	0.25	7.46
		MALLORY-WEISS SYNDROME	n/a	72	100.0	1	1.4	0.25	7.46
		NAUSEA	n/a	72	100.0	1	1.4	0.25	7.46
		TOOTHACHE	n/a	72	100.0	2	2.8	0.77	9.57
		VOMITING	n/a	72	100.0	3	4.2	1.43	11.55
	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	-Total	n/a	72	100.0	20	27.8	18.76	39.05
		ASTHENIA	n/a	72	100.0	1	1.4	0.25	7.46
		CHEST PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		CHILLS	n/a	72	100.0	1	1.4	0.25	7.46
		FATIGUE	n/a	72	100.0	3	4.2	1.43	11.55
		GRANULOMA	n/a	72	100.0	1	1.4	0.25	7.46
		IMPAIRED HEALING	n/a	72	100.0	1	1.4	0.25	7.46
		INFLUENZA LIKE ILLNESS	n/a	72	100.0	1	1.4	0.25	7.46
		INJECTION SITE IRRITATION	n/a	72	100.0	1	1.4	0.25	7.46

		INJECTION SITE REACTION	n/a	72	100.0	12	16.7	9.80	26.91
		MALaise	n/a	72	100.0	2	2.8	0.77	9.57
		MASS	n/a	72	100.0	1	1.4	0.25	7.46
		PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		PERIPHERAL SWELLING	n/a	72	100.0	2	2.8	0.77	9.57
		PYREXIA	n/a	72	100.0	2	2.8	0.77	9.57
	IMMUNE SYSTEM DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		ALLERGY TO CHEMICALS	n/a	72	100.0	1	1.4	0.25	7.46
	INFECTIONS AND INFESTATIONS	-Total	n/a	72	100.0	16	22.2	14.17	33.09
		ASYMPTOMATIC COVID-19	n/a	72	100.0	1	1.4	0.25	7.46
		COVID-19	n/a	72	100.0	2	2.8	0.77	9.57
		EPIDIDYMITIS	n/a	72	100.0	1	1.4	0.25	7.46
		FEBRILE INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
		FUNGAL SKIN INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
		GASTRIC ULCER HELICOBACTER	n/a	72	100.0	1	1.4	0.25	7.46
		GASTROINTESTINAL INFECTION	n/a	72	100.0	2	2.8	0.77	9.57
		IMPETIGO	n/a	72	100.0	1	1.4	0.25	7.46
		INFECTED DERMAL CYST	n/a	72	100.0	1	1.4	0.25	7.46
		INFLUENZA	n/a	72	100.0	3	4.2	1.43	11.55
		NASOPHARYNGITIS	n/a	72	100.0	4	5.6	2.18	13.43
		ORAL HERPES	n/a	72	100.0	1	1.4	0.25	7.46
		RHINITIS	n/a	72	100.0	3	4.2	1.43	11.55
		UPPER RESPIRATORY TRACT INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
		URINARY TRACT INFECTION	n/a	72	100.0	1	1.4	0.25	7.46
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	10	13.9	7.72	23.71
		ACCIDENTAL OVERDOSE	n/a	72	100.0	1	1.4	0.25	7.46
		CHEST INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		FALL	n/a	72	100.0	4	5.6	2.18	13.43
		JOINT DISLOCATION	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		LIGAMENT SPRAIN	n/a	72	100.0	1	1.4	0.25	7.46
		LIMB INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		RIB FRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
		SCRATCH	n/a	72	100.0	1	1.4	0.25	7.46
		SOFT TISSUE INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		THERMAL BURN	n/a	72	100.0	1	1.4	0.25	7.46
		TOOTH FRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
	INVESTIGATIONS	-Total	n/a	72	100.0	4	5.6	2.18	13.43
		BLOOD PHOSPHORUS DECREASED	n/a	72	100.0	1	1.4	0.25	7.46
		CARDIAC MURMUR	n/a	72	100.0	1	1.4	0.25	7.46
		HEPATIC ENZYME INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
		PLATELET COUNT DECREASED	n/a	72	100.0	1	1.4	0.25	7.46
	METABOLISM AND NUTRITION DISORDERS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		HYPERGLYCAEMIA	n/a	72	100.0	1	1.4	0.25	7.46

		VITAMIN D DEFICIENCY	n/a	72	100.0	2	2.8	0.77	9.57
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	-Total	n/a	72	100.0	17	23.6	15.30	34.60
		ARTHRALGIA	n/a	72	100.0	9	12.5	6.72	22.08
		ARTHROPATHY	n/a	72	100.0	1	1.4	0.25	7.46
		BURSITIS	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT CONTRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT EFFUSION	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT STIFFNESS	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT SWELLING	n/a	72	100.0	1	1.4	0.25	7.46
		MUSCULOSKELETAL DISCOMFORT	n/a	72	100.0	1	1.4	0.25	7.46
		MUSCULOSKELETAL STIFFNESS	n/a	72	100.0	1	1.4	0.25	7.46
		MYALGIA	n/a	72	100.0	1	1.4	0.25	7.46
		NECK PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		OSTEOARTHRITIS	n/a	72	100.0	1	1.4	0.25	7.46
		PAIN IN EXTREMITY	n/a	72	100.0	5	6.9	3.00	15.25
		TENDONITIS	n/a	72	100.0	1	1.4	0.25	7.46
	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		SKIN PAPILLOMA	n/a	72	100.0	1	1.4	0.25	7.46
	NERVOUS SYSTEM DISORDERS	-Total	n/a	72	100.0	12	16.7	9.80	26.91
		HEAD DISCOMFORT	n/a	72	100.0	1	1.4	0.25	7.46
		HEADACHE	n/a	72	100.0	10	13.9	7.72	23.71
		LETHARGY	n/a	72	100.0	1	1.4	0.25	7.46
		MORTON'S NEURALGIA	n/a	72	100.0	1	1.4	0.25	7.46
	PSYCHIATRIC DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		ANXIETY	n/a	72	100.0	1	1.4	0.25	7.46
	RENAL AND URINARY DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		RENAL COLIC	n/a	72	100.0	1	1.4	0.25	7.46
	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	-Total	n/a	72	100.0	3	4.2	1.43	11.55
		HAEMATOSPERMIA	n/a	72	100.0	1	1.4	0.25	7.46
		PENILE BLISTER	n/a	72	100.0	1	1.4	0.25	7.46
		TESTICULAR PAIN	n/a	72	100.0	1	1.4	0.25	7.46
	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	-Total	n/a	72	100.0	7	9.7	4.79	18.74
		COUGH	n/a	72	100.0	2	2.8	0.77	9.57
		DYSPNOEA	n/a	72	100.0	1	1.4	0.25	7.46
		OROPHARYNGEAL PAIN	n/a	72	100.0	3	4.2	1.43	11.55
		RHINITIS ALLERGIC	n/a	72	100.0	1	1.4	0.25	7.46
		RHINORRHOEA	n/a	72	100.0	1	1.4	0.25	7.46
	SKIN AND SUBCUTANEOUS TISSUE DISORDERS	-Total	n/a	72	100.0	11	15.3	8.75	25.32
		ACNE	n/a	72	100.0	1	1.4	0.25	7.46
		DERMATITIS ALLERGIC	n/a	72	100.0	3	4.2	1.43	11.55
		ECZEMA	n/a	72	100.0	3	4.2	1.43	11.55
		ERYTHEMA	n/a	72	100.0	2	2.8	0.77	9.57
		HENOCH-SCHONLEIN PURPURA	n/a	72	100.0	1	1.4	0.25	7.46
		RASH ERYTHEMATOUS	n/a	72	100.0	1	1.4	0.25	7.46
		RASH PRURITIC	n/a	72	100.0	1	1.4	0.25	7.46



--	--	--	--	--	--	--	--	--	--

95% CI based on Wilson Scores.  
Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGRI\_SG.xls  
21MAR2022 11:32

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 1  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	BLOOD AND LYMPHATIC SYSTEM DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		IRON DEFICIENCY ANAEMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	EAR AND LABYRINTH DISORDERS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	2	3.9	1.08	13.22
		CERUMEN IMPACTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		EAR PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		OTORRHOEA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		VERTIGO	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	EYE DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		UVEITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	GASTROINTESTINAL DISORDERS	-Total	Mild	21	29.2	6	28.6	13.81	49.96
			Moderate	51	70.8	9	17.6	9.57	30.25
		ABDOMINAL PAIN UPPER	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
		DIARRHOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		FOOD POISONING	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTRITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTROINTESTINAL DISORDER	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTROESOPHAGEAL REFLUX DISEASE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		HAEMORRHOIDS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		HAEMORRHOIDS THROMBOSED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		HIATUS HERNIA	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	1	2.0	0.35	10.30
		LARGE INTESTINE POLYP	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		MALLORY-WEISS SYNDROME	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		NAUSEA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		TOOTHACHE	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
		VOMITING	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	-Total	Mild	21	29.2	6	28.6	13.81	49.96
			Moderate	51	70.8	14	27.5	17.11	40.95
		ASTHENIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CHEST PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CHILLS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		FATIGUE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		GRANULOMA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		IMPAIRED HEALING	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INFLUENZA LIKE ILLNESS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INJECTION SITE IRRITATION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INJECTION SITE REACTION	Mild	21	29.2	4	19.0	7.67	40.00
			Moderate	51	70.8	8	15.7	8.17	28.01
		MALAISE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		MASS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		PERIPHERAL SWELLING	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
		PYREXIA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
	IMMUNE SYSTEM DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		ALLERGY TO CHEMICALS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	INFECTIONS AND INFESTATIONS	-Total	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	13	25.5	15.55	38.87
		ASYMPTOMATIC COVID-19	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		COVID-19	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	2	3.9	1.08	13.22
		EPIDIDYMITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FEBRILE INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FUNGAL SKIN INFECTION	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		GASTRIC ULCER HELICOBACTER	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		GASTROINTESTINAL INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		IMPETIGO	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		INFECTED DERMAL CYST	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		INFLUENZA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		NASOPHARYNGITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	4	7.8	3.09	18.50
		ORAL HERPES	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RHINITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		UPPER RESPIRATORY TRACT INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		URINARY TRACT INFECTION	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	9	17.6	9.57	30.25
		ACCIDENTAL OVERDOSE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CHEST INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FALL	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	3	5.9	2.02	15.92
		JOINT DISLOCATION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		JOINT INJURY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		LIGAMENT SPRAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		LIMB INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RIB FRACTURE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SCRATCH	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SOFT TISSUE INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		THERMAL BURN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		TOOTH FRACTURE	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	1	2.0	0.35	10.30
	INVESTIGATIONS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	3	5.9	2.02	15.92
		BLOOD PHOSPHORUS DECREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		CARDIAC MURMUR	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HEPATIC ENZYME INCREASED	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PLATELET COUNT DECREASED	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	METABOLISM AND NUTRITION DISORDERS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
		HYPERGLYCAEMIA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		VITAMIN D DEFICIENCY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	1	2.0	0.35	10.30
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	-Total	Mild	21	29.2	8	38.1	20.75	59.12
			Moderate	51	70.8	9	17.6	9.57	30.25
		ARTHRALGIA	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	6	11.8	5.51	23.38
		ARTHROPATHY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		BURSITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		JOINT CONTRACTURE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		JOINT EFFUSION	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		JOINT STIFFNESS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		JOINT SWELLING	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		MUSCULOSKELETAL DISCOMFORT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MUSCULOSKELETAL STIFFNESS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MYALGIA	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		NECK PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		OSTEOARTHRITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PAIN IN EXTREMITY	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	3	5.9	2.02	15.92
		TENDONITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	-Total	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	1	2.0	0.35	10.30
		SKIN PAPILLOMA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	NERVOUS SYSTEM DISORDERS	-Total	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	9	17.6	9.57	30.25
		HEAD DISCOMFORT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HEADACHE	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	8	15.7	8.17	28.01
		LETHARGY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		MORTON'S NEURALGIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	PSYCHIATRIC DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		ANXIETY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	RENAL AND URINARY DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RENAL COLIC	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
		HAEMATOSPERMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PENILE BLISTER	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		TESTICULAR PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	7	13.7	6.81	25.72
		COUGH	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		DYSPNOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		OROPHARYNGEAL PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		RHINITIS ALLERGIC	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RHINORRHOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	SKIN AND SUBCUTANEOUS TISSUE DISORDERS	-Total	Mild	21	29.2	3	14.3	4.98	34.64
			Moderate	51	70.8	8	15.7	8.17	28.01
		ACNE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		DERMATITIS ALLERGIC	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	1	2.0	0.35	10.30
		ECZEMA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		ERYTHEMA	Mild	21	29.2	1	4.8	0.85	22.67

			Moderate	51	70.8	1	2.0	0.35	10.30
		HENOCH-SCHONLEIN PURPURA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RASH ERYTHEMATOUS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		RASH PRURITIC	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR1\_SG.xls

21MAR2022 11:32

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 2  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	GASTROINTESTINAL DISORDERS	-Total	n/a	72	100.0	5	6.9	3.00	15.25
		ABDOMINAL PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		COLITIS ULCERATIVE	n/a	72	100.0	1	1.4	0.25	7.46
		DIARRHOEA	n/a	72	100.0	1	1.4	0.25	7.46
		GASTRITIS	n/a	72	100.0	1	1.4	0.25	7.46
		GASTROESOPHAGEAL REFLUX DISEASE	n/a	72	100.0	1	1.4	0.25	7.46
		MELAENA	n/a	72	100.0	1	1.4	0.25	7.46
	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		PYREXIA	n/a	72	100.0	1	1.4	0.25	7.46
	IMMUNE SYSTEM DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		SEASONAL ALLERGY	n/a	72	100.0	1	1.4	0.25	7.46
	INFECTIONS AND INFESTATIONS	-Total	n/a	72	100.0	8	11.1	5.74	20.42
		COVID-19	n/a	72	100.0	3	4.2	1.43	11.55
		CYSTITIS	n/a	72	100.0	1	1.4	0.25	7.46
		DIVERTICULITIS	n/a	72	100.0	1	1.4	0.25	7.46
		ERYSIPELAS	n/a	72	100.0	1	1.4	0.25	7.46
		LOWER RESPIRATORY TRACT INFECTION	n/a	72	100.0	2	2.8	0.77	9.57
		NASOPHARYNGITIS	n/a	72	100.0	1	1.4	0.25	7.46
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	5	6.9	3.00	15.25
		CLOSED GLOBE INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		CONTUSION	n/a	72	100.0	1	1.4	0.25	7.46
		JOINT INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		LIGAMENT SPRAIN	n/a	72	100.0	1	1.4	0.25	7.46
		LIP INJURY	n/a	72	100.0	1	1.4	0.25	7.46
		MUSCLE STRAIN	n/a	72	100.0	1	1.4	0.25	7.46
		WRIST FRACTURE	n/a	72	100.0	1	1.4	0.25	7.46
	INVESTIGATIONS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		ALANINE AMINOTRANSFERASE INCREASED	n/a	72	100.0	1	1.4	0.25	7.46



		ASPARTATE AMINOTRANSFERASE INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
		BLOOD PRESSURE INCREASED	n/a	72	100.0	1	1.4	0.25	7.46
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	-Total	n/a	72	100.0	5	6.9	3.00	15.25
		ARTHRALGIA	n/a	72	100.0	2	2.8	0.77	9.57
		BACK PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		OSTEOARTHRITIS	n/a	72	100.0	1	1.4	0.25	7.46
		SYNOVIAL CYST	n/a	72	100.0	1	1.4	0.25	7.46
	NERVOUS SYSTEM DISORDERS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		HEADACHE	n/a	72	100.0	2	2.8	0.77	9.57
	PSYCHIATRIC DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		DEPRESSION	n/a	72	100.0	1	1.4	0.25	7.46
	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		SLEEP APNOEA SYNDROME	n/a	72	100.0	1	1.4	0.25	7.46
	VASCULAR DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		HYPERTENSION	n/a	72	100.0	1	1.4	0.25	7.46

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR2\_SG.xls

21MAR2022 11:33

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 2  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	GASTROINTESTINAL DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	4	7.8	3.09	18.50
		ABDOMINAL PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		COLITIS ULCERATIVE	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		DIARRHOEA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTRITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		GASTROESOPHAGEAL REFLUX DISEASE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MELAENA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		PYREXIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	IMMUNE SYSTEM DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SEASONAL ALLERGY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INFECTIONS AND INFESTATIONS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	6	11.8	5.51	23.38
		COVID-19	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		CYSTITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		DIVERTICULITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		ERYSIPELAS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		LOWER RESPIRATORY TRACT INFECTION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22

		NASOPHARYNGITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	4	7.8	3.09	18.50
		CLOSED GLOBE INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CONTUSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		JOINT INJURY	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		LIGAMENT SPRAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		LIP INJURY	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MUSCLE STRAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		WRIST FRACTURE	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INVESTIGATIONS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
		ALANINE AMINOTRANSFERASE INCREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		ASPARTATE AMINOTRANSFERASE INCREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		BLOOD PRESSURE INCREASED	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	4	7.8	3.09	18.50
		ARTHRALGIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		BACK PAIN	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		OSTEOARTHRITIS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		SYNOVIAL CYST	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	NERVOUS SYSTEM DISORDERS	-Total	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
		HEADACHE	Mild	21	29.2	2	9.5	2.65	28.91
			Moderate	51	70.8	0	0.0	0.00	7.00
	PSYCHIATRIC DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46

			Moderate	51	70.8	1	2.0	0.35	10.30
		DEPRESSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		SLEEP APNOEA SYNDROME	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
	VASCULAR DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HYPERTENSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR2\_SG.xls

21MAR2022 11:33

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 3  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	GASTROINTESTINAL DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		MALLORY-WEISS SYNDROME	n/a	72	100.0	1	1.4	0.25	7.46
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		CONCUSSION	n/a	72	100.0	1	1.4	0.25	7.46
	METABOLISM AND NUTRITION DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		HYPERGLYCAEMIA	n/a	72	100.0	1	1.4	0.25	7.46
	RENAL AND URINARY DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		RENAL COLIC	n/a	72	100.0	1	1.4	0.25	7.46

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR3\_SG.xls  
 21MAR2022 11:36

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 3  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	GASTROINTESTINAL DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MALLORY-WEISS SYNDROME	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CONCUSSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	METABOLISM AND NUTRITION DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HYPERGLYCAEMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	RENAL AND URINARY DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		RENAL COLIC	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR3\_SG.xls  
 21MAR2022 11:36

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade 4**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		FOREIGN BODY IN GASTROINTESTINAL TRACT	n/a	72	100.0	1	1.4	0.25	7.46

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR4\_SG.xls  
 21MAR2022 11:39

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 4  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FOREIGN BODY IN GASTROINTESTINAL TRACT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR4\_SG.xls  
 21MAR2022 11:39



POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade >= 3  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	GASTROINTESTINAL DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		MALLORY-WEISS SYNDROME	n/a	72	100.0	1	1.4	0.25	7.46
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		CONCUSSION	n/a	72	100.0	1	1.4	0.25	7.46
		FOREIGN BODY IN GASTROINTESTINAL TRACT	n/a	72	100.0	1	1.4	0.25	7.46
	METABOLISM AND NUTRITION DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		HYPERGLYCAEMIA	n/a	72	100.0	1	1.4	0.25	7.46
	RENAL AND URINARY DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		RENAL COLIC	n/a	72	100.0	1	1.4	0.25	7.46

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR35\_SG.xls  
 21MAR2022 11:37

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade >= 3  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	GASTROINTESTINAL DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MALLORY-WEISS SYNDROME	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		CONCUSSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FOREIGN BODY IN GASTROINTESTINAL TRACT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	METABOLISM AND NUTRITION DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HYPERGLYCAEMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	RENAL AND URINARY DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		RENAL COLIC	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEGR35\_SG.xls  
 21MAR2022 11:37

POPULATION: All Treated Patients  
 ENDPOINT: Any SAEs  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% Lower CL	95% Upper CL
All	GASTROINTESTINAL DISORDERS	-Total	n/a	72	100.0	2	2.8	0.77	9.57
		ABDOMINAL PAIN	n/a	72	100.0	1	1.4	0.25	7.46
		MALLORY-WEISS SYNDROME	n/a	72	100.0	1	1.4	0.25	7.46
	INFECTIONS AND INFESTATIONS	-Total	n/a	72	100.0	3	4.2	1.43	11.55
		COVID-19	n/a	72	100.0	1	1.4	0.25	7.46
		DIVERTICULITIS	n/a	72	100.0	1	1.4	0.25	7.46
		ERYSIPELAS	n/a	72	100.0	1	1.4	0.25	7.46
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	n/a	72	100.0	3	4.2	1.43	11.55
		CONCUSSION	n/a	72	100.0	1	1.4	0.25	7.46
		CONTUSION	n/a	72	100.0	1	1.4	0.25	7.46
		FOREIGN BODY IN GASTROINTESTINAL TRACT	n/a	72	100.0	1	1.4	0.25	7.46
	METABOLISM AND NUTRITION DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		HYPERGLYCAEMIA	n/a	72	100.0	1	1.4	0.25	7.46
	RENAL AND URINARY DISORDERS	-Total	n/a	72	100.0	1	1.4	0.25	7.46
		RENAL COLIC	n/a	72	100.0	1	1.4	0.25	7.46

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AESAE\_SG.xls  
 21MAR2022 11:45

POPULATION: All Treated Patients  
 ENDPOINT: Any SAEs  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

				Emicizumab (N=72)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% Lower CL	95% Upper CL
Hemophilia severity	GASTROINTESTINAL DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	2	3.9	1.08	13.22
		ABDOMINAL PAIN	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		MALLORY-WEISS SYNDROME	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INFECTIONS AND INFESTATIONS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	2	3.9	1.08	13.22
		COVID-19	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		DIVERTICULITIS	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		ERYSIPELAS	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	3	5.9	2.02	15.92
		CONCUSSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		CONTUSION	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		FOREIGN BODY IN GASTROINTESTINAL TRACT	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	METABOLISM AND NUTRITION DISORDERS	-Total	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
		HYPERGLYCAEMIA	Mild	21	29.2	0	0.0	0.00	15.46
			Moderate	51	70.8	1	2.0	0.35	10.30
	RENAL AND URINARY DISORDERS	-Total	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00
		RENAL COLIC	Mild	21	29.2	1	4.8	0.85	22.67
			Moderate	51	70.8	0	0.0	0.00	7.00

--	--	--	--	--	--	--	--	--	--

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AESAE\_SG.xls

21MAR2022 11:45

POPULATION: All Treated Patients  
ENDPOINT: AEs leading to treatment discontinuation  
MODEL: --  
STUDY: BO41423  
Dichotomous Analysis (Safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.  
Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw\_soc.sas  
Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_soc\_DEC21\_TRT\_AEDIS\_SG.xls  
21MAR2022 11:31

**Roche Standard AEGT - Anaphylactic reactions Sampsons - 30 Jun 2010 - cat A narrow**

PT	Anaphylactic reaction Anaphylactic shock Anaphylactic transfusion reaction Anaphylactoid reaction Anaphylactoid shock ASIA syndrome Circulatory collapse Dialysis membrane reaction Idiopathic environmental intolerance Kounis syndrome Multisystem inflammatory syndrome Multisystem inflammatory syndrome in adults Procedural shock Pseudoallergic reaction Shock Shock symptom Type I hypersensitivity
----	---

**Roche Standard AEGT - Anaphylactic reactions Sampsons -30 Jun 2010 - cat B upper airway/respiratory**

PT	Acute respiratory failure Asthma Atopic cough Bronchial oedema Bronchospasm Cardio-respiratory distress Chest discomfort Choking Choking sensation Circumoral oedema Cough Cyanosis Dyspnoea Hyperventilation
----	--

Irregular breathing
Laryngeal dyspnoea
Laryngeal oedema
Laryngospasm
Laryngotracheal oedema
Mouth swelling
Nasal obstruction
Oedema mouth
Oropharyngeal oedema
Oropharyngeal spasm
Oropharyngeal swelling
Pharyngeal oedema
Pharyngeal swelling
Respiratory arrest
Respiratory distress
Respiratory failure
Reversible airways obstruction
Sensation of foreign body
Sneezing
Stridor
Swollen tongue
Tachypnoea
Throat clearing
Throat tightness
Tongue oedema
Tracheal obstruction
Tracheal oedema
Upper airway obstruction
Wheezing



**Roche Standard AEGT - Anaphylactic reactions Sampsons -30 Jun 2010 - cat C angioedema/urticaria**

PT	Acquired C1 inhibitor deficiency
	Allergic oedema
	Allergic stomatitis
	Angioedema
	Circumoral swelling
	Erythema
	Eye oedema
	Eye pruritus
	Eye swelling
	Eyelid oedema
	Face oedema
	Flushing
	Injection site urticaria
	Lip erythema
	Lip oedema
	Lip swelling
	Nodular rash
	Ocular hyperaemia
	Oedema
	Oedema blister
	Periorbital oedema
	Pruritus
	Pruritus allergic
	Rash
	Rash erythematous
	Rash pruritic
	Skin swelling
	Swelling
	Swelling face
	Urticaria
	Urticaria papular

<b>Roche Standard AEGT - Anaphylactic reactions Sampsons -30 Jun 2010- cat D cardiovascular/hypotension</b>	
PT	<ul style="list-style-type: none"> <li>Blood pressure decreased</li> <li>Blood pressure diastolic decreased</li> <li>Blood pressure systolic decreased</li> <li>Cardiac arrest</li> <li>Cardio-respiratory arrest</li> <li>Cardiovascular insufficiency</li> <li>Diastolic hypotension</li> <li>Hypotension</li> <li>Hypotensive crisis</li> <li>Post procedural hypotension</li> </ul>
<b>Roche Standard AEGT - Anaphylactic reactions Sampsons -30 Jun 2010- cat E gastrointestinal symptoms</b>	
PT	<ul style="list-style-type: none"> <li>Abdominal pain</li> <li>Abdominal pain lower</li> <li>Abdominal pain upper</li> <li>Abdominal rigidity</li> <li>Abdominal tenderness</li> <li>Gastrointestinal pain</li> <li>Oesophageal pain</li> <li>Retching</li> <li>Vomiting</li> <li>Vomiting projectile</li> </ul>

**POPULATION: All Treated Patients**  
**ENDPOINT: AESI: Systemic hypersensitivity/anaphylactic/anaphylactoid reaction**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI1\_SG.xls  
 21MAR2022 10:58

POPULATION: All Treated Patients

ENDPOINT: AESI: Systemic hypersensitivity/anaphylactic/anaphylactoid reaction, Intensity/Grade >=3

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI1G35\_SG.xls

21MAR2022 10:59

**POPULATION: All Treated Patients**  
**ENDPOINT: AESI: Thromboembolic event (TE)**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	1	1.4	0.25	7.46
Hemophilia severity	Mild	21	29.2	1	4.8	0.85	22.67
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI2\_SG.xls  
 21MAR2022 11:00

POPULATION: All Treated Patients

ENDPOINT: AESI: Thromboembolic event (TE), Intensity/Grade >=3

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI2G35\_SG.xls

21MAR2022 11:08

**POPULATION: All Treated Patients**  
**ENDPOINT: AESI: Thrombotic microangiopathy (TMA)**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI3\_SG.xls  
 21MAR2022 11:10

POPULATION: All Treated Patients

ENDPOINT: AESI: Thrombotic microangiopathy (TMA), Intensity/Grade >=3

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI3G35\_SG.xls

21MAR2022 11:11



POPULATION: All Treated Patients

ENDPOINT: AESI: Suspected transmission of an infectious agent by the study drug

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI4\_SG.xls

21MAR2022 11:13

POPULATION: All Treated Patients

ENDPOINT: AESI: Suspected transmission of an infectious agent by the study drug, Intensity/Grade >=3

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI4G35\_SG.xls

21MAR2022 11:17

**POPULATION: All Treated Patients**  
**ENDPOINT: AESI: Potential drug-induced liver injury**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI5\_SG.xls  
 21MAR2022 11:18

POPULATION: All Treated Patients

ENDPOINT: AESI: Potential drug-induced liver injury, Intensity/Grade >=3

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESI5G35\_SG.xls

21MAR2022 11:19

**POPULATION: All Treated Patients**  
**ENDPOINT: Serious AESI: Systemic hypersensitivity/anaphylactic/anaphylactoid reaction**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_SAESI1\_SG.xls  
 21MAR2022 11:20

**POPULATION: All Treated Patients**  
**ENDPOINT: Serious AESI: Thromboembolic event (TE)**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_SAESI2\_SG.xls  
 21MAR2022 11:21

**POPULATION: All Treated Patients**  
**ENDPOINT: Serious AESI: Thrombotic microangiopathy (TMA)**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_SAESI3\_SG.xls  
 21MAR2022 11:22

POPULATION: All Treated Patients

ENDPOINT: Serious AESI: Suspected transmission of an infectious agent by the study drug

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_SAESI4\_SG.xls

21MAR2022 11:23



**POPULATION: All Treated Patients**  
**ENDPOINT: Serious AESI: Potential drug-induced liver injury**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_SAESI5\_SG.xls  
 21MAR2022 11:24

POPULATION: All Treated Patients  
 ENDPOINT: --  
 MODEL: --  
 STUDY: BO41423  
 Outcome of Adverse Events

		Emicizumab (N=72)														
		Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events		n	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any AEs																
	All	248	213	85.9	0	0.0	22	8.9	0	0.0	13	5.2	0	0.0	0	0.0
	Grade 1	203	178	87.7	0	0.0	15	7.4	0	0.0	10	4.9	0	0.0	0	0.0
	Grade 2	40	30	75.0	0	0.0	7	17.5	0	0.0	3	7.5	0	0.0	0	0.0
	Grade >=3	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 3	4	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 4	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 5	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Any SAEs																
	All	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 1	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 2	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 3	4	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 4	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 5	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Any AESIs																
	All	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 1	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 2	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 3	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 4	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Grade 5	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_resolved.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_resolved\_DEC21\_TRT.xls  
 21MAR2022 11:50

POPULATION: All Treated Patients  
 ENDPOINT: Any AEs, excluding AEs 'DISEASE UNDER STUDY'  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	60	83.3	73.09	90.20
Hemophilia severity	Mild	21	29.2	18	85.7	65.36	95.02
	Moderate	51	70.8	42	82.4	69.75	90.43

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEALL\_DISST\_SG.xls  
 28APR2022 15:43

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade 1, excluding AEs 'DISEASE UNDER STUDY'**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	35	48.6	37.43	59.93
Hemophilia severity	Mild	21	29.2	10	47.6	28.34	67.63
	Moderate	51	70.8	25	49.0	35.86	62.32

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR1\_DISST\_SG.xls  
 28APR2022 15:45

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 2, excluding AEs 'DISEASE UNDER STUDY'  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	22	30.6	21.13	41.95
Hemophilia severity	Mild	21	29.2	7	33.3	17.19	54.63
	Moderate	51	70.8	15	29.4	18.71	43.00

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR2\_DISST\_SG.xls  
 28APR2022 15:46

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 3, excluding AEs 'DISEASE UNDER STUDY'  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	2	2.8	0.77	9.57
Hemophilia severity	Mild	21	29.2	1	4.8	0.85	22.67
	Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR3\_DISST\_SG.xls  
 28APR2022 15:46

POPULATION: All Treated Patients  
 ENDPOINT: AEs Intensity/Grade 4, excluding AEs 'DISEASE UNDER STUDY'  
 MODEL: --  
 STUDY: BO41423  
 Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	1	1.4	0.25	7.46
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	1	2.0	0.35	10.30

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR4\_DISST\_SG.xls  
 28APR2022 15:47

**POPULATION: All Treated Patients**  
**ENDPOINT: AEs Intensity/Grade >= 3, excluding AEs 'DISEASE UNDER STUDY'**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	3	4.2	1.43	11.55
Hemophilia severity	Mild	21	29.2	1	4.8	0.85	22.67
	Moderate	51	70.8	2	3.9	1.08	13.22

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEGR35\_DISST\_SG.xls  
 28APR2022 15:47



**POPULATION: All Treated Patients**  
**ENDPOINT: Any SAEs, excluding AEs 'DISEASE UNDER STUDY'**  
**MODEL: --**  
**STUDY: BO41423**  
**Dichotomous Analysis (Safety)**

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	7	9.7	4.79	18.74
Hemophilia severity	Mild	21	29.2	2	9.5	2.65	28.91
	Moderate	51	70.8	5	9.8	4.26	20.98

95% CI based on Wilson Scores.  
 Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas  
 Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AESAE\_DISST\_SG.xls  
 28APR2022 15:49

POPULATION: All Treated Patients

ENDPOINT: AEs leading to treatment discontinuation, excluding AEs 'DISEASE UNDER STUDY'

MODEL: --

STUDY: BO41423

Dichotomous Analysis (Safety)

		Emicizumab (N=72)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% Lower CL	95% Upper CL
All	n/a	72	100.0	0	0.0	0.00	5.07
Hemophilia severity	Mild	21	29.2	0	0.0	0.00	15.46
	Moderate	51	70.8	0	0.0	0.00	7.00

95% CI based on Wilson Scores.

Clinical cut-off: 30OCT2021

Program: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_BASE/prod/program/saf\_raw.sas

Output: root/clinical\_studies/RO5534262/CDT30282/BO41423/data\_analysis/ACE\_202112\_CSRPrimary/prod/output/saf\_raw\_DEC21\_TRT\_AEDIS\_DISST\_SG.xls

28APR2022 15:44